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ABSTRACT OF DISSERTATION 
PRECLINICAL TARGETING OF TREM2 FOR THE TREATMENT OF 
ALZHEIMER’S DISEASE-TYPE PATHOLOGY IN A TRANSGENIC MOUSE 
MODEL 
Alzheimer's disease (AD) is defined as a progressive neurodegenerative 
disorder and is characterized by a devastating mental decline. There are three 
pathological hallmarks of the disease necessary for its diagnosis, these are 
extracellular amyloid plaques comprised of beta-amyloid (Ab) protein, intracellular 
neurofibrillary tangles comprised of hyperphosphorylated tau protein, and marked 
neuronal loss. Active immunization against Ab1-42 or passive immunization with 
monoclonal anti-Ab antibodies has been shown to reduce amyloid deposition and 
improve cognition in transgenic mouse models of AD, aged beagles, and 
nonhuman primates. Unfortunately, due to cerebrovascular adverse events, both 
active and passive immunization strategies targeting Ab have failed in clinical 
trials. It is, therefore, necessary to identify novel amyloid-clearing therapeutics that 
do not induce cerebrovascular adverse events. We hypothesized that 
neuroinflammatory modulation could be a potential novel target. 
Triggering receptor expressed on myeloid cells-2 (TREM2) is a lipid and 
lipoprotein binding receptor expressed exclusively in the brain by microglia. 
Homozygous TREM2 loss of function mutations cause early-onset progressive 
presenile dementia while heterozygous, function-reducing point mutations triple 
the risk of sporadic, late-onset AD. Heterozygous TREM2 point mutations, which 
reduce either ligand binding or cell surface expression, are associated with a 
reduction in the number of microglia surrounding amyloid plaques, microglial 
inability to phagocytose compact Ab deposits and form a barrier between plaques 
and neurons, an increase in the number of phospho- tau-positive dystrophic 
neurites and increased tau in the cerebrospinal fluid. Heterozygous mutations also 
double the rate of brain atrophy and decrease the age of AD onset by 3-6 years. 
Although human genetics support the notion that loss of TREM2 function 
exacerbates neurodegeneration, it is unclear whether activation of TREM2 in a 
disease state is beneficial. 
The work we present here characterizes a TREM2 agonizing antibody as a 
potential therapeutic for amyloid reduction. We found that its administration results 
in immune modulation, recruitment of microglia to the site of amyloid plaques, 
reduced amyloid deposition and improvement in spatial learning and novel object 
recognition memory in the 5xFAD model of AD. More specifically, we show that 
intracranial injection of TREM2 agonizing antibodies into the frontal cortex and 
hippocampus of 5xFAD mice leads to clearance of diffuse and compact amyloid. 
We also show that systemic injection of TREM2 agonizing antibodies weekly over 
a period of 14 weeks results in clearance of diffuse and compact amyloid as well 
as elevated plasma concentrations of Ab1-40 and Ab1-42. Furthermore, systemic 
administration of these antibodies led to immune modulation and enhanced 
cognitive performance on radial arm water maze and novel object recognition 
tests. Importantly, we show the TREM2 agonizing antibody does not induce the 
adverse cerebrovascular events known to accompany amyloid modifying 
therapies. Though systemic administration of both TREM2 agonizing and anti-Ab 
antibodies does not further enhance amyloid clearance or cognitive performance, 
co-administration mitigates the adverse cerebrovascular events associated with 
anti-Ab antibodies.  
Collectively, these data indicate TREM2 activators may be an effective 
therapeutic target for the treatment of AD.  
KEYWORDS: Alzheimer’s Disease, Immunotherapy, Microglia, TREM2, Adverse 
Cerebrovascular Events. 
Brittani Rae Price
April 15, 2019
PRECLINICAL TARGETING OF TREM2 FOR THE TREATMENT OF 
ALZHEIMER’S DISEASE-TYPE PATHOLOGY IN A TRANSGENIC MOUSE 
MODEL 
By 
Brittani Rae Price 
Donna M Wilcock, Ph.D. 
Director of Dissertation 
Kenneth S Campbell, Ph.D. 
Director of Graduate Studies 
April 15, 2019
Dedicated to those that thought my dreams were unattainable, your doubt was 
my inspiration. 
	 iii 
ACKNOWLEDGEMENTS  
First and foremost, I’d like to thank all those that believed in and 
encouraged me along the way. I would not be here without your continued love 
and support.  
Donna, I can’t even begin to thank you. Thank you for taking a chance on 
me, encouraging me, and challenging me. Thank you for allowing me to pursue 
everything I wanted to learn and accomplish, and for fueling me with caffeine, 
seltzer water, and wine as I did it. Above everything else, thank you for believing 
in me even when I didn’t believe in myself. I’ve said it before, and I’ll say it again: 
when I grow up, I want to be like you. If I am ever half the woman or half the 
scientist you are, I will consider both my life and career a success.  
Tiffany, I’m at loss for words (which, as you know, rarely happens). I can’t 
begin to thank you for your patience while teaching me various techniques and 
answering my incessant questions. Thank you for accompanying me on 
countless trips to Speedway for diet coke and sour patch kids, for willingly 
wandering the streets of Dresden just so I could find a reasonably sized coffee, 
and for vouching to the Holland TSA agent that I am in no way a flight risk. Thank 
you for listening to me rant, for letting me eat lunch in your office, and for your 
willingness to partake in shenanigans from time to time. There is no one I’d 
rather be stranded in a foreign country with, clean out a (rather toxic) cold room 
with, or manage 300 abnormally aggressive mice with. You have become one of 
my very best friends and I couldn’t have made it this far without your 
encouragement. I owe you my sanity.  
Erica, thank you for being such an excellent role model, for always sharing 
advice and feedback, and for teaching me to run RAWM (I think it’s safe to say 
which of those I’m least thankful for).  Thank you for being equally as dramatic as 
I am, for loving Tim Horton’s as much as I do, and for appreciating the use of a 
well-played GIF as much as I do. Thank you for partaking in and supporting the 
shenanigans Tiffany and I design, and for letting me serenade you with one hit 
wonders from the early 2000s. Sorry I made you listen to Song of the South on 
repeat that one time, I thought you would like it. Like Tiffany, you’ve become one 
of my best friends and I couldn’t have made it this far without you. But don’t 
worry, we both know I’ll be embarrassing you for years to come.  
Chelsea, thank you for being equally as passionate about improving the 
gradual school experience as I am. I’m so proud of the work we’ve done and will 
do. Despite the numerous frustrations we faced, you never considered giving 
up—you’re amazing, thank you. I could not have asked for a better partner, we 
truly are a dream team. Any chance I can recruit you to Boston?  
Mom, you have always worked incredibly hard and put my needs above 
your own. It is because of you that I understand what hard work looks like. It is 
because of your example that I have made it to where I am today. Thank you. 
Oh, and thank you for introducing me to wine, it has been quite helpful 
throughout the writing process.  
Dad, you taught me how to dribble a basketball, wash a car, do a proper 
squat, and the importance of keeping my word. Most importantly, you taught me 
how to persevere in spite of the limitations others set for me. You have always 
iv 
believed in me and for that, I am forever grateful. It is an honor to be your 
daughter.  
Morgan, thank you for your unwavering support, unnecessarily long 
snapchats, and love of coffee and breakfast food. You’re constantly making me 
laugh and remind me not to take life or myself too seriously. Although I begged 
mom to return you when I was 5, I’m proud to be your big sister.  
Johnny, thank you for being patient when I chose to work weekends or 
stay up late to read, write, or study. Thank you for agreeing to uproot yourself 
and move to Boston this May. And thank you for never doubting me. I could not 
have done this without you, or your willingness to make me a fresh pot of coffee 
any time I asked. You’re an incredible partner and dog-dad, I can’t wait to see 
what our future holds.  
v 
TABLE OF CONTENTS 
Acknowledgements...............................................................................................iii 
List of Figures.......................................................................................................vii 
Chapter 1: Introduction 
Alzheimer’s Disease 
Alzheimer’s Disease.........................................................................1 
Topographic Distribution of AD-Associated Pathology....................4 
The Amyloid Cascade Hypothesis...................................................5 
           Mouse Models 
Transgenic Mouse Models of AD……............................................10  
Behavioral Analyses of Transgenic Mice.......................................14 
 Targeting Neuroinflammation for the Treatment of Alzheimer’s Disease..17 
         TREM2………………………………………………………………….27 
Chapter 2: TREM2 Activation Recruits Microglia, Ameliorates Amyloid 
Deposition, and Improves Cognition in a Model of Amyloid Deposition. 
           Abstract....................................................................................................34 
           Introduction..............................................................................................36 
 Methods…..……………………………………………………………………38 
 Results.....................................................................................................45 
 Discussion...............................................................................................50 
Chapter 3: Intracranial Co-administration of TREM2 Agonizing and anti-
Ab Antibodies Does Not Further Augment Amyloid Clearance in the 5XFAD 
Model of AD Despite Unique Neuroinflammatory Responses 
           Abstract.....................................................................................................63 
Introduction...............................................................................................64 
Methods....................................................................................................68 
Results......................................................................................................74 
           Discussion.................................................................................................75 
Chapter 4: Agonism of TREM2 by an Activating Antibody Ameliorates 
Cerebrovascular Events Normally Associated with anti-Ab Immunotherapy 
Abstract....................................................................................................87 
Introduction..............................................................................................88 
Methods...................................................................................................90 
Results.....................................................................................................98 
 Discussion..............................................................................................101 
Chapter 5: Discussion........................................................................................120 
References.........................................................................................................141 
vi 
Vita.....................................................................................................................161 
vii 
LIST OF FIGURES 
Figure 1.1, Amyloid Cascade Hypothesis…………………………………………..31 
Figure 1.2, TREM2 Signaling Cascade……………………………………………..32 
Figure 1.3, Gene Expression in DAM Microglia………………………………...….33 
Figure 2.1, AL-002a Promoted TREM2-dependent DAP12 and SYK 
Phosphorylation………………………………………………………………………..55 
Figure 2.2, Intracranial Injection of AL-002a Activates Microglia and 
Ameliorates Amyloid Deposition in 5XFAD Mice…………………………………..57 
Figure 2.3, Systemic Administration of AL-002a Improves Learning 
and    Memory and Lowers Amyloid Deposition in 5XFAD Mice…………………59 
Figure 2.4, Neuroinflammatory Changes are Apparent Following 
AL-002a Treatment……………………………………………………………………61 
Figure 3.1, Engagement of Both the Microglial Fcg and TREM2 Surface 
Immunoreceptors Induces Receptor-mediated Endocytosis……………………..80 
Figure 3.2, Intracranial Co-administration of TREM2-agonizing and 
anti-Ab Antibodies Does Not Lead to Additive Reductions in Ab………………...81 
Figure 3.3, Biochemical Quantification Reveals Intracranial  
Co-administration of AL-002a and anti-Ab Does Not Doubly Reduced 
Insoluble Ab1-40 or Ab1-42……………………………………………………………...83 
Figure 3.4, Biochemical Quantification Reveals Intracranial  
Co-administration  
of AL-002a and anti-Ab Does Not Doubly Reduced Soluble Ab1-40
or Ab1-42………………………………………………………………………………...84 
Figure 3.5, Pro-inflammatory Cytokines Whose Expression Was 
Significantly Influenced by Antibody Treatment……………………………………85 
Figure 3.6, Pro-inflammatory Cytokines Whose Expression Was Not 
Significantly Influenced by Antibody Treatment………………………………..….86 
Figure 4.1, Systemic Administration of AL-002a, anti-Ab, and a Combination 
of the Two Improves Spatial Learning and Memory in 5XFAD Mice,  
but Fails to Significantly Effect Cognition in Wildtype Mice……………………...107 
Figure 4.2, Systemic Administration of AL-002a, anti-Ab, and a Combination 
of the Two Improves Recognition Memory in 5XFAD, but  
Fails to Significantly Effect Cognition in Wildtype Mice…………………...….….109 
Figure 4.3, Systemic Co-administration of AL-002a and anti-Ab 
anti-Ab Antibodies Does Not Lead to Additive Reductions in Ab……………….110 
Figure 4.4, Biochemical Quantification Reveals Systemic Co-administration 
of AL-002a and anti-Ab Does Not Additively Reduce Soluble or Insoluble  
Ab Species……………………………………………………………………………112 
Figure 4.5, Systemic Administration of AL-002a and a Combination of 
the Two Enhances Microglial Staining……………………………………...……..113 
Figure 4.6, Pro-inflammatory Cytokines Whose Expression Was 
Significantly Influenced by Antibody Treatment…………………………...……..115 
Figure 4.7, Pro-inflammatory Cytokines Whose Expression Was Not 
Significantly Influenced by Antibody Treatment…………………………...……..117 
Figure 4.8, Biochemical Quantification Reveals that Treatment with 
viii 
anti-Ab Increases MMP System Markers…………………………………...…….118 
Figure 4.9, Treatment with anti-Ab Increases the Incidence of 
Prussian Blue Detected Microhemorrhages………………………………………119 
Figure 5.1, Schematic Showing the Arrangement of Cells of the 
Neurovascular Unit…………………………………………………………………..139 
Figure 5.2, The Proposed Mechanism by which the anti-Ab Antibody, 
but Not AL-002a, Induces Cerebrovascular Adverse Events……………...……140 
1 
Chapter 1 
Introduction 
Alzheimer’s Disease 
The term dementia is used to describe cognitive impairment severe enough 
to impact activities of daily living, otherwise referred to as basic self-care tasks, 
such as routine meals, oral care, bathing, etc. Considering dementia is an umbrella 
term used to describe a clinical syndrome, it should be understood that the 
dementia phenotype can be attributed to a number of distinct diseases. Of the 
diseases that cause dementia, Alzheimer’s disease is the most common etiology 
accounting for roughly 60% of all dementia cases [1]. First described by German 
psychiatrist Alois Alzheimer in 1906, Alzheimer’s disease (AD) is a progressive 
neurodegenerative disease characterized by a devastating mental decline and 
serves as the sixth leading cause of death in the United States today [1, 2]. 
Although AD symptoms vary widely among individuals, the most common 
initial symptom is a worsening ability to remember new information [1]. Other 
common symptoms include: memory loss resulting in a disruption of daily life, 
trouble planning or solving problems, difficulty completing routine tasks, confusion 
regarding time or place, challenges understanding images and visual-spatial 
relationships, misplacing items and losing the ability to retrace one’s steps, 
disinhibition, reclusive behavior, alterations in mood and personality, and 
increased anxiety, agitation and sleep disturbances [1]. Like the symptoms 
themselves, the rate at which symptoms progress from mild to severe varies widely 
among affected individuals. Currently, there is no single test for a clinical diagnosis 
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of probable AD. Rather, diagnosis requires a comprehensive medical evaluation 
for which the patient must provide a medical and family history, undergo cognitive 
tests, physical and neurological examinations, blood tests, and neuroimaging. 
Currently, a clinical diagnosis of AD can only be confirmed by pathological 
assessment at the time of autopsy.  
Pathologically confirmed AD diagnoses require the presence of three 
hallmark pathologies: extracellular amyloid plaques comprised of the amyloid-beta 
(Ab) protein, neurofibrillary tangles comprised of intraneuronal inclusions of 
hyperphosphorylated tau protein, and marked neuronal loss [3]. The pathogenic 
Ab peptide is derived from the larger amyloid precursor protein (APP), which is 
cleaved by a, b, and g secretases. Approximately 90% of cellular APP is cleaved 
by a secretase, generating sAPPa and the CTFa fragment [4]. Subsequent g-
secretase cleavage of CTFa produces a benign, truncated fragment that does not 
aggregate [4]. By contrast, the remaining 10% of cellular APP is sequentially 
cleaved by the b and g secretases. b secretase first cleaves APP at amino acid 
671 to release a large secreted derivative, sAPPb [4]. The resulting CTFb fragment 
remains membrane-bound where it is then rapidly cleaved by g secretase to 
generate the Ab peptide [4]. However, unlike cleavage by b secretase, cleavage 
by g secretase can occur at either amino acid 711 or 713 and is therefore 
somewhat imprecise [4]. This imprecise cleavage generates Ab peptides of varying 
amino acid lengths (Ab1-40 and Ab1-42, respectively) and accounts for the C-terminal 
heterogeneity of the Ab peptide population. The slightly longer 42 amino acid 
species of Ab (Ab1-42) is more hydrophobic and fibrillogenic then shorter Ab species 
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[4]. As a result, Ab1-42 is the principal species deposited in amyloid plaques. 
However, accumulation of the Ab peptide is not limited to amyloid plaques of the 
brain parenchyma but is also observed in the brain vasculature as cerebral amyloid 
angiopathy (CAA). In contrast to parenchymal depositions comprised primarily of 
Ab1-42, CAA contains both Ab1-40 and Ab1-42, with Ab1-40 being the major isoform 
present [5]. Ab1-40 has also been reportedly shown to colocalize with Ab1-42 in 
parenchymal deposits of amyloid. It is important to note Ab can also be deposited 
as diffuse plaques, often thought to be an intermediate step in the formation of the 
compact amyloid plaques referred to above.  
By contrast, neurofibrillary tangles (NFTs) are intraneuronal cytoplasmic 
bundles of paired, helically wound filaments comprised of hyperphosphorylated tau 
protein [6]. Under physiological conditions, tau modulates the stability of axonal 
microtubules. Tau contains 85 phosphorylation sites and so it is not surprising 
phosphorylation at any of these sites profoundly impacts its function [7]. Under 
pathological conditions such as AD, tau becomes hyperphosphorylated, reducing 
its affinity for microtubules and destabilizing the cytoskeleton of the affected 
neuron [7]. Additionally, hyperphosphorylation of tau promotes aberrant assembly 
of tau into insoluble aggregates that induce synaptic dysfunction and neuronal cell 
death.  
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Topographic Distribution of AD-Associated Pathology 
Throughout the progression of AD, amyloid plaques and neurofibrillary 
tangles are initially observed in different areas of the brain: amyloid pathology is 
first observed in the neocortex whereas neurofibrillary tangles are first observed in 
allocortical structures [3, 8-11]. As to be expected, the distribution patterns of 
amyloid and neurofibrillary tangle pathology also differ throughout disease 
progression. In 1995, a landmark paper by Braak and Braak characterized the 
regional distribution of neurofibrillary tangles, known today as the six-part Braak 
staging system of AD [3]. According to Braak staging, the distribution pattern of 
neurofibrillary tangles in AD begins in the transentorhinal cortex (stages I) then 
advances to include the CA1 region of the hippocampus (stage II) and limbic 
structures such as the subiculum (stage III) and amygdala and thalamus (stage IV) 
[3]. This expansion of pathology continues until virtually all subdivisions of the 
cerebral cortex are consumed with neurofibrillary tangle pathology (stages V-VI) 
[3]. Conversely, amyloid plaques accumulate mainly in the neocortex. While the 
spatiotemporal pattern of progression of amyloid deposition is less predictable than 
that of neurofibrillary tangles, in 2002 Thal et al. proposed a staging system that is 
still in use today [10]. Thal staging proposes 5 stages: 1) Stage 1, characterized 
by the accumulation of amyloid deposits in the neocortex, 2) Stage 2, involves 
additional amyloid deposition in the entorhinal cortex, hippocampus, and 
amygdala, 3) Stage 3, involves additional deposition in the striatum, thalamus, 
hypothalamus and white matter, 4) Stage 4, involves additional deposition in the 
 5 
red nucleus, reticular formation of the medulla oblongata and the substantia nigra, 
and 5) Stage 5, involves additional deposition in the pons and cerebellum [10]. 
 
The Amyloid Cascade Hypothesis  
To date, AD pathogenesis is widely believed to be driven by the production 
and deposition of the Ab peptide in amyloid plaques. First conceptualized by John 
Hardy and Gerald Higgins in 1992, the amyloid cascade hypothesis proposes 
neurofibrillary tangles, neuronal loss, vascular damage, and dementia are the 
direct result of Ab deposition in the form of diffuse and compact, neuritic plaques 
[12]. More specifically, this hypothesis suggests the pathological progression of 
AD follows a temporal sequence with Ab deposition triggering neurofibrillary tangle 
formation, synaptotoxicity, mitochondrial dysfunction, chronic neuroinflammation 
arising from aberrant activation of microglia and astrocytes, and ultimately 
dementia (Figure 1.1) [13, 14]. Despite growing controversy surrounding this 
hypothesis, it continues to provide the main theoretical construct for AD due to a 
large body of supporting evidence.  
Much of the support for the amyloid cascade hypothesis is derived from 
genetic mutations known to cause familial, early-onset AD (EOAD) which is 
characterized by a mean age of onset of less than 65 years. Mutations in either 
APP or the core catalytic subunit of g-secretase, presenilin 1 (PSEN1) or presenilin 
2 (PSEN2), either increase the overall production of Ab or increase the production 
of Ab1-42 specifically. Granted, EOAD accounts for only 5% of AD cases. Additional 
support for the amyloid cascade hypothesis comes from the most significant 
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genetic risk factor for late-onset AD (LOAD), apolipoprotein E (ApoE), a plasma 
protein involved in the transport of cholesterol and other lipids. The ApoE gene 
contains several single-nucleotide polymorphisms (SNPs) resulting in three 
common isoforms of ApoE: ApoE2 (cys112, cys158), ApoE3 (cys112, arg158), and 
ApoE4 (arg112, arg158) [15]. Though the three isoforms differ only by one or two 
amino acids, these differences profoundly influence ApoE structure and function 
[15, 16]. Of the three isoforms, ApoE3 is the most common and is not believed to 
play a significant role in AD. While ApoE2 is associated with a lower risk for AD, 
possession of an ApoE4 allele is the strongest genetic risk factor for LOAD and 
CAA or a combination of both disorders, given it impairs Ab clearance in the brain 
[15, 17, 18]. Yet, possession of the ApoE4 allele does not guarantee that a person 
will develop LOAD, simply that they have a significantly increased risk compared 
to someone with no ApoE4 alleles. Overall, genetic risk factors and mutations for 
LOAD and EOAD, respectively, support the amyloid cascade hypothesis given 
they increase Ab deposition either by enhancing amyloidogenic processing of APP 
or by inducing disruption in Ab clearance mechanisms.  
Further support for the amyloid cascade hypothesis comes from individuals 
with Down syndrome. First described by J. Langdon Down in 1866 and identified 
as a chromosome 21 trisomy by Jerome Lejeune in 1959, Down syndrome is one 
of the most common causes of intellectual disability [19-21]. It’s well known that 
Down syndrome is characterized by facial dysmorphology, deficits in the immune 
and endocrine systems and delayed cognitive development, but a lesser known 
feature of Down syndrome is that affected adults experience an increased risk for 
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developing AD as they age. Coinciding with this age-dependent risk, almost all 
Down syndrome adults over the age of 40 exhibit neuropathology sufficient for an 
AD diagnosis [21]. This is because APP is located on chromosome 21 and the 
most common form of Down syndrome, trisomy 21, leads to an overexpression of 
APP. In Down syndrome individuals with complete trisomy 21, extracellular Ab 
accumulates in diffuse plaques starting at age 30 [21, 22], after which amyloid 
plaques and neurofibrillary tangles continue to rapidly accumulate until they reach 
a threshold sufficient for AD diagnosis by age 40 [21, 23]. Conversely, individuals 
with partial trisomy of chromosome 21 that does not result in duplication of the APP 
locus develop Down syndrome but not AD [24], whereas individuals presenting 
only small internal chromosome 21 duplications that result in three copies of APP 
develop EOAD but do not develop Down syndrome [25]. Thus, overexpression of 
APP is strongly linked to Ab deposition in adult life.  
Additional support for the amyloid cascade hypothesis arises from studies 
of Ab-induced synaptic dysfunction and synaptotoxicity. Synaptic plasticity is the 
process by which specific patterns of synaptic activity alter synaptic strength over 
time. Long-term potentiation (LTP) is a form of activity-dependent plasticity which 
results in the enhancement of synaptic transmission, whereas long-term 
depression (LTD) is a form of activity-dependent plasticity that leads to reduced 
efficacy of synaptic transmission. Both LTP and LTD are important for learning and 
memory. LTP and LTD are regulated by the activity of two ionotropic receptors for 
glutamate: N-methyl-D-aspartate receptors (NMDARs) and a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPARs). Induction of LTP requires 
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activation of NMDARs, leading to large post-synaptic increases in Ca2+ and 
activation of downstream signaling events that involve re-localization of new 
AMPARs to the plasma membrane [26]. AMPARs are redistributed to the plasma 
membrane to potentiate the synapse (LTP) or removed from the plasma 
membrane to weaken the synapse (LTD). Studies suggest that A -induced 
excitotoxicity results from aberrant stimulation of NMDARs, likely resulting from 
impaired regulation of glutamate levels [14, 27, 28]. Excess glutamate in the 
synaptic cleft may desensitize NMDARs, preventing sufficient post-synaptic Ca2+ 
influx and LTP induction [29]. Furthermore, increased Ab levels have been 
associated with increased AMPAR internalization and thus enhanced LTD [30]. 
These studies are further supported by others demonstrating that preventing the 
overstimulation of NMDARs with partial antagonists mitigates axonal transport 
deficits in primary neuronal cultures and hippocampal slices from rats and mice 
[31, 32]. Coincident with these studies, partial NMDAR antagonism is said to 
account for the beneficial clinical effect of memantine when prescribed for AD [33].  
Finally, support for the amyloid cascade hypothesis comes from two rat 
studies. In 2008, Shankar et al. demonstrated that injection of Ab1-42 directly 
isolated from AD brains leads to impaired synaptic plasticity and memory in 
otherwise healthy rats [34, 35]. In 2011, Jin et al. demonstrated that human Ab1-42 
oligomers induced hyperphosphorylation of tau in cultured rat neurons [34]. 
Despite compelling evidence in support of the amyloid cascade hypothesis, 
data from a number of studies are inconsistent with its linear structure. One major 
objection for the amyloid cascade hypothesis is the fact that Ab deposition can 
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occur in nondemented elderly individuals. In fact, one study found that only 17% 
of nondemented elderly individuals had few or no degenerative brain changes at 
the time of autopsy [36], while another demonstrated that between 20-40% met 
criteria for neuropathological diagnosis of AD despite having an average MMSE 
score of 28.1 prior to death [37]. Furthermore, amyloid-PET studies have shown 
that a substantial amyloid burden can be observed in the brains of nondemented 
elderly individuals [38, 39], supporting the estimate that 10-30% of this patient 
population has amyloid-positive brain scans [40]. Granted, the most compelling 
argument against the amyloid cascade hypothesis is derived from numerous failed 
Ab-targeted immunotherapy trials.  
In 2002, a participant of the first active Ab1-42 immunotherapy trial (AN1792) 
died due to conditions unrelated to the vaccine, thereby allowing neuropathologists 
to examine the effects of Ab1-42 immunotherapy for the first time. The autopsy 
revealed extensive areas of the cerebral cortex were devoid of plaques, although 
plaques remained present in other cortical areas along with residual tau pathology 
[41]. A follow-up study examined 9 additional participants of the AN1792 trial and 
found that those receiving the vaccine presented a reduction in Ab load compared 
to unimmunized controls, though reductions in Ab load and the degree of plaque 
removal was variable [42]. Unfortunately, despite enhanced clearance and 
subsequent reductions in Ab1-42, a long-term clinical follow up study found AN1792 
participants experienced no cognitive benefits [43]. Rather, this study showed that 
all participants exhibited progressive cognitive decline until the time of death, 
including 2 participants that presented virtually no plaque pathology at the time of 
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autopsy [43, 44]. To date, these findings have been corroborated by several other 
groups [45-47]. Similarly, passive immunotherapy trials have also failed.  
These studies suggest that amyloid deposition and the dementia 
characteristic of AD are mutually exclusive and therefore serve as a substantial 
challenge to the amyloid cascade hypothesis. However, it is important to note that 
these data do not negate the fact that Ab1-42 is toxic, but rather suggest the field 
reconsider its reliance on what has potentially become an overwhelming dogma.  
 
Transgenic Mouse Models of AD 
 Transgenic mouse models became an aim for researchers following the 
discovery of genetic mutations in the APP, PS1, and PS2 genes causative of 
EOAD. In 1996 Duff et al. reported that mice overexpressing the M146L mutation 
in PS1 showed a selective increase in brain Ab1-42 compared to wildtype 
littermates, however, these mice did not deposit amyloid in diffuse or compact 
plaques [48]. Fortunately, mice expressing mutations in the APP gene showed 
greater promise.  
 First described by Games et al., the PDAPP mouse is one of the earliest 
transgenic mouse models of AD. The PDAPP model expresses APP 695, APP 751 
and APP 770 with the Indiana mutation (V717F) under the control of the platelet-
derived growth factor (PDGF) promoter [49]. Starting at 4 months of age, this 
model exhibits cognitive deficits in a variety of tasks. In fact, cognitive deficits are 
observed prior to amyloid deposition which is first seen between 4 and 6 months 
of age, accelerates rapidly between 7 and 9 months of age, and reveals significant 
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numbers of both diffuse and compact deposits in the frontal cortex and 
hippocampus by 12 months of age [49]. GFAP-positive astrocytes and activated 
microglia have also been shown to associate with plaques in this model [49]. 
Interestingly, while there are no paired helical filaments or aggregates present in 
this model, phosphorylated tau immunoreactivity has been observed in dystrophic 
neurites after 14 months of age [50].  
To date, one of the most well characterized and widely used mouse models 
of AD is the Tg2576 model. Developed by Karen Hsiao Ashe, the Tg2576 model 
overexpresses the APP 695 with the Swedish mutation (KM670/671NL) under the 
control of the hamster prion protein promoter [51]. Tg2576 mice have detectable 
diffuse and compact amyloid deposits by 6 months of age and exhibit extensive 
parenchymal plaque deposition by 11-13 months of age [52]. The Tg2576 model 
has also been shown to exhibit an increase in microglial density and size in plaque 
forming areas [53], synaptic loss by 4.5 months of age [54], and deficits in LTP by 
5 months of age [55]. Some studies show Tg2576 mice have impaired spatial 
learning and deficits in working memory and contextual fear conditioning by 6 
months of age, while others report normal cognition at this age with progressive 
impairment starting at 12 months of age. It may be noted this discrepancy likely 
arises because the mice carry the Pde6brd1 retinal degeneration allele that may 
induce light sensitivity or blindness and affect the results of behavioral testing.  
 In an effort to produce a transgenic model that demonstrated reproducible 
cognitive and memory deficits, the M146L PS1 mouse was crossed with the 
Tg2576 APP mouse to create the PS/APP mouse. First described by Holcomb et 
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al. in 1998, the PS/APP model exhibits an early, selective increase in brain levels 
of Ab1-42 followed by accelerated Ab deposition, with amyloid plaques occupying 
large areas of the neocortex and hippocampus by 16 months of age [56]. 
Coincident with plaque deposition, there is a substantial increase in plaque-
associated microglia and astrocytes, indicating a substantial neuroinflammatory 
response between 6 and 16 months of age [57]. Importantly, PS/APP mice exhibit 
reproducible age-dependent behavioral deficits as assessed by both the Morris 
and radial arm water mazes [58]. Interestingly, while neurofibrillary tangles are not 
observed in this model, hyperphosphorylated tau is detectable as punctate 
deposits near amyloid plaques in the cortex and hippocampus starting at 24 weeks 
of age [59]. Additionally, neuronal loss in the CA1 region of the hippocampus has 
been demonstrated in 22-month-old PS/APP mice [60].  
 Although the aforementioned models exhibit amyloid plaque pathology 
similar to that observed in AD, they develop this pathology slowly. In 2006, in an 
effort to accelerate the development of amyloid pathology and investigate the 
effects of very high cerebral Ab1-42 levels, Oakley et al. generated the 5xFAD model 
of AD. 5xFAD mice express 3 APP mutations (Swedish K670N/M671L, Florida 
I716V, and London V717I) and 2 PS1 mutations (M146L and L286V), each driven 
by the mouse Thy1 promoter [61]. As a result of expressing 5 distinct AD-
associated mutations, the 5xFAD model rapidly develops severe amyloid 
pathology. These mice accumulate intraneuronal Ab1-42 starting at 1.5 months of 
age with amyloid deposition rapidly following at 2 months and continuing to 
increase with age. Gliosis begins at 2 months of age coincident with plaque 
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deposition, synapse degeneration is then observed by 4 months of age along with 
neuronal loss and behavioral deficits [61]. 
 Although these amyloid-depositing models are useful for testing therapies 
targeting amyloid specifically, they fail to incorporate neurofibrillary tangle 
pathology. As a result, the P301L tau transgenic model was developed in the lab 
of Mike Hutton in 2000. P301L mice carry a transgene encoding human tau that 
contains the P301L mutation under the control of the mouse prion promoter [62]. 
This model develops neurofibrillary tangle pathology in an age and gene-dose 
dependent manner; by 4.5 months of age in homozygotes and 6.5 months of age 
in heterozygotes [62]. Unfortunately, due to the expression of P301L tau in the 
brain stem and spinal cord, this model also develops motor deficits that render the 
mice completely paralyzed by 12 months of age [62]. Moreover, mice show 
differential expression between males and females, with females having 3-4 times 
greater expression of P301L tau [62]. Despite these disadvantages, it has been 
shown that crossing the P301L mouse with the Tg2576 mouse (APPSwe-Tau 
model) enhances forebrain neurofibrillary tangle pathology, further suggesting the 
presence of Ab influences the extent of neurofibrillary pathology [63]. However, it 
should be noted that this model exhibits motor disturbances similar to those 
observed in the P301L mouse [63]. 
 Fortunately, the 3xTg model displays both plaque and tangle pathology 
without any physical or behavioral abnormalities. The 3xTg model was generated 
by injecting single-cell embryos from mice with knock-in of PS1 with the M146V 
mutation with two human transgenes (APP with the Swedish mutation and tau with 
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the P301L mutation), both under the control of the mouse Thy1.2 promoter [64]. 
Extracellular Ab deposits are evident by six months of age, with tau pathology 
apparent by 12 months of age [65]. 3xTg mice also demonstrate age-dependent 
LTP impairment although this occurs prior to the development of any AD-like 
pathology [64]. Cognitive impairment has been shown to manifest by 4 months of 
age as a deficit in long-term retention, however, neither amyloid nor tau pathology 
is present at this time point [66].  
 Though these models have been pivotal for our current understanding of 
AD, because the vast majority of AD cases arise not from autosomal dominant 
mutations causative of EOAD but through a complex interaction of polymorphisms 
and environmental risk factors that accrue over time, significant progress remains 
to be made in the creation of the ideal mouse model.  
 
Behavioral Analyses of Transgenic Mice 
 As previously discussed, AD symptoms center on cognitive impairment, 
thus any proposed clinical therapy will only be deemed effective if it improves 
learning and memory. As such, cognitive assessment is crucial in preclinical 
studies. Several behavioral paradigms have been developed to assess cognitive 
impairment in mice.  
 First described by Richard Morris in 1982, the Morris water maze is 
consistently used to assess memory retention [67]. The test is comprised of a 
water pool with a hidden escape platform that the mouse must locate using either 
local or contextual clues. This test takes advantage of a mouse’s natural aversion 
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to water and swimming, using this aversion to encourage mice to seek out the 
hidden platform. Measurements include the time taken to locate the platform 
(escape latency) and the time spent in the quadrant where the platform was once 
removed (probe trials) [67]. The Morris water maze has been shown to be heavily 
hippocampal dependent given lesions to the hippocampus or its cholinergic inputs 
significantly impair performance [67].  
 A commonly used modification of the Morris water maze is known as the 
radial arm water maze (RAWM). The RAWM consists of a circular pool with six 
swim alleys (arms) radiated out from an open central area and a submerged 
escape platform at the end of one of the arms. Similar to the Morris water maze, 
the mouse must locate the escape platform using spatial cues present on the walls 
of the testing room. Mice complete thirty trials over the course of two days, during 
which the platform remains in the same arm (goal arm) for each mouse but the 
arm in which the mouse starts each trial is different [68]. Alternating the start arm 
requires the mouse to use the visual cues to remember where the platform is [69]. 
Both the time taken to find the platform and the number of wrong arms entered 
(errors) is measured [68]. Like the Morris water maze, the RAWM is a heavily 
hippocampal dependent spatial learning and memory task.  
 In contrast to the Morris and radial arm water mazes described above, novel 
object recognition (NOR) is a short-term memory task that exploits a mouse’s 
innate predisposition to explore new objects [70]. NOR is comprised of two phases 
of testing: a familiarization phase and a test phase. During the familiarization 
phase, the mouse is presented with, and explores, two identical copies of an object 
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(object A) in the test environment. Following a delay period, the mouse undergoes 
the test phase which involves presenting a new copy of object A and a novel object 
B in the same test environment. If the mouse preferentially orients to and explores 
object B, an inference is made that the mouse recognized object A as familiar, 
thereby displaying a sensitivity to discriminate old from new [71]. On the other 
hand, if the mouse orients to and explores both objects A and B equally, it is 
assumed that the mouse is unable to perform the recognition discrimination [71]. 
NOR task performance is quantified using the Discrimination Ratio (DR), which 
reflects the duration of exploration of the novel object compared to the familiar 
object as a proportion of the mouse’s total exploration time [72]. NOR has been 
shown to be heavily dependent upon the integrity of the perirhinal cortex given that 
lesions of the perirhinal cortex reliably lead to NOR task performance deficits [73]. 
 Another widely used behavioral paradigm for assessing memory is known 
as contextual fear conditioning. Contextual fear conditioning is employed using an 
aversive stimulus, commonly a small electric shock, coupled to sound. Throughout 
this task mice learn to freeze when the sound is heard as it is associated with the 
aversive stimulus and the extent of freezing is then measured [74]. If a mouse fails 
to freeze it is assumed it exhibits impaired memory of the preceding events [75]. 
While this task is highly dependent upon the integrity of the amygdala it is also 
sensitive to disruptions in hippocampal function. 
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Targeting Neuroinflammation for the Treatment of Alzheimer’s Disease 
In addition to its three hallmark pathologies, AD is characterized by an 
extensive neuroinflammatory response, of which microglia and astrocytes are the 
principal regulators. This pathological feature of AD was uncovered by autopsy 
reports from the 1980s demonstrating the presence of immune-related antigens 
and cells surrounding amyloid plaques in the brains of AD and Down syndrome 
patients [76-78]. While these initial reports challenged the previously assumed 
view that the brain was immunologically privileged due to the blood-brain-barrier 
(BBB), additional reports from the 1990s led to the concept of neuroinflammation 
[79-81]. Today, neuroinflammation is at the forefront of AD research, both for its 
contribution to the neurodegenerative process and for its role in the clearance of 
AD lesions.  
As the brain’s resident macrophages, microglia are crucial contributors to 
homeostasis and immune defense. Under homeostatic conditions, microglia 
regulate neuronal proliferation and differentiation as well as synaptogenesis [82, 
83]. Additionally, as part of the innate immune system, microglia constantly survey 
the brain parenchyma for signals of external danger [84]. del Rio-Hortega first 
identified microglia in 1932, describing them as a small population of phagocytic 
migratory cells within the CNS [85]. It wasn’t until 1939 that he coined the term 
microglia. Because microglia exhibit morphology and phagocytic capacity similar 
to that of macrophages, del Rio-Hortega hypothesized microglia may be derived 
from blood monocytes [85]. These observations ultimately gave way to the long-
supported prevailing viewpoint that microglia, like macrophages, are of monocyte 
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origin. However, a landmark study published in 2010 by Florent Ginhoux and 
colleagues proved this viewpoint false. In this study, Ginhoux et al. used fate-
mapping analysis to reveal that microglia are derived from primitive yolk-sac 
macrophages and subsequent studies have shown that microglia self-renew via 
local proliferation under homeostatic conditions [86, 87]. Conversely, in the context 
of neurodegeneration, bone marrow-derived (BM) macrophages can infiltrate the 
CNS, however, this infiltration has been shown to require BBB disruption as well 
as the induction of specific chemokines [88-90].  
del Rio-Hortega’s original characterization of microglia also described the 
cell’s ability to respond to brain injury by migrating to sites of tissue damage, 
undergoing marked changes in morphology, proliferating, and engulfing tissue 
debris [85]. It wasn’t until the 1980s when methods for culturing microglia in vitro 
and reagents for visualizing cells in situ were developed, that subsequent studies 
identified two principal forms of microglia: amoeboid or “activated” microglia and 
ramified or “resting” microglia. Activated microglia were described as being 
morphologically similar to monocytes and macrophages whereas resting microglia 
were described as having processes [91]. One study compared microglial cultures 
to macrophages and demonstrated a number of similarities in morphology, cellular 
functions, cell surface antigens and immunohistochemical properties [91].  
 Macrophages are leukocytes that monitor their tissue environment and 
respond rapidly to perturbations based on the stimuli they are presented with. The 
heterogeneity of their responses warranted a phenotypic classification system in 
which macrophages are said to be polarized to either an M1 or M2 phenotype. 
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Macrophages activated by IFN-g or TNFa secrete proinflammatory cytokines, 
produce reactive oxygen and nitrogen species, and are considered to be 
classically activated, M1 macrophages. It is important to note that M1 
macrophages exhibit high microbicidal activity and therefore serve as an important 
defense mechanism that can cause damage if not tightly regulated [92]. 
Conversely, M2 or alternatively activated, macrophages are associated with anti-
inflammatory cytokine expression and are further subdivided into three types: M2a, 
M2b, and M2c. M2a macrophages are stimulated by IL-4 or IL-13 and described 
as wound healing and repair macrophages given they secrete mediators shown to 
contribute to extracellular matrix (ECM) deposition and remodeling [93]. M2b 
macrophages are instead stimulated by immune complexes, toll-like receptor 
activation or IL-1 receptor ligands and represent a combined M1/M2a phenotype. 
Finally, M2c macrophages are stimulated by IL-10 and are often referred to as 
regulatory macrophages with anti-inflammatory activity [94, 95]. It is important to 
note that M2c macrophages contribute to an environment that enhances survival 
as opposed to the neutralization of pathogens. Because microglia have been 
shown to express many of the same neuroinflammatory markers as macrophages, 
the neuroinflammation field extended the M1/M2 taxonomy to classify microglia. 
This classification system was then used to harness new neuroinflammation-
targeted therapies for AD in the early 2000s.  
  In 1998 E.G. McGeer and P.L. McGeer introduced the concept of the 
autotoxic loop and subsequently the neuroinflammation hypothesis of AD. The 
autotoxic loop was described by McGeer and McGeer as a “vicious cycle” in which 
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microglia were activated as a consequence of amyloid pathology [96]. Activated 
microglia then said to result in the secretion cytotoxic cytokines that induced rapid 
neuronal death and provided cellular debris that further exacerbated the process 
[96]. This hypothesis was ultimately supported by the finding that cytokine levels 
are increased in the brains and cerebrospinal fluid (CSF) of AD patients [97]. 
However, a number of successive studies demonstrated the levels of these 
cytokines are not sufficient to or sustained enough to cause substantial neuronal 
damage. In fact, attempts to recreate the autotoxic loop in transgenic mouse 
models of AD revealed that the initiation of an inflammatory response in the brain 
leads to the clearance of amyloid plaques; a finding that ultimately led to one of 
the most extensively explored potential therapies for AD: anti-A  immunotherapy.  
  In 1999, Dale Schenk and colleagues demonstrated that active 
immunization with Ab1-42 prevents plaque formation, neuritic dystrophy, and 
astrogliosis in 6-week-old PDAPP mice [98]. Furthermore, this study demonstrated 
that immunization with Ab1-42 reduces Ab deposition in aged, 11-month-old PDAPP 
mice [98]. Subsequent studies in transgenic mice, aged beagles, and nonhuman 
primates indicated that active immunization with Ab1-42 improves cognition in 
addition to reducing Ab deposition [99-102]. The first anti-Ab immunotherapy trial, 
AN-1792, was initiated as a result of these findings. AN-1792 consisted of a 
synthetic, full-length Ab1-42 peptide formulated in the QS-21 adjuvant [103]. 
Although no adverse events were reported in Phase 1, 6% of the 372 trial 
participants in Phase 2a developed aseptic meningoencephalitis [104]. Though 
affected participants responded well to treatment with corticosteroids, the risk was 
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deemed too high and the vaccine was ultimately discontinued. As previously 
discussed, it wasn’t until the first participant of the AN-1792 trial died that a 
beneficial effect of the vaccine was observed. The failure of this active 
immunization trial ultimately encouraged scientists to explore passive 
immunization strategies. 
 In 2003, Wilcock et al. demonstrated that bilateral intracranial injection of 
an anti-Ab1-42 monoclonal antibody dramatically reduced the Ab load in mice [105]. 
This study showed that diffuse Ab levels were significantly reduced by 24 hours 
post-injection, but it wasn’t until 72 hours post-injection that compact plaque 
deposition was reduced [105]. This early reduction in Ab load was shown to occur 
in the absence of the microglial activation markers CD45 and MHC-ll, whereas 
reduction of compact plaques was shown to occur in association with microglial 
activation [105]. This temporal association of compact amyloid reduction with 
microglial activation suggested that microglial activation is crucial for the clearance 
of compact, fibrillogenic amyloid deposits. The authors deduced that between 24 
and 72 hours activated microglia near amyloid deposits likely phagocytose 
opsonized amyloid via Fcg- or complement-mediated mechanisms [105, 106]. In 
2004, this same group demonstrated that weekly intraperitoneal injections of an 
anti-Ab1-42 monoclonal antibody reversed learning and memory deficits in aged, 
APP-transgenic mice [107]. Although dramatic reductions in amyloid deposition 
were observed, this study also found a significant increase in vascular amyloid 
deposition and the number of microhemorrhages in the brain following 
immunization; Granted, it may be noted that cognitive benefits persisted in the 
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presence of these cerebrovascular pathologies [107]. Soon after, Pfeifer et al. 
demonstrated that spontaneous microhemorrhages were significantly increased in 
APP23 mice following 5 months of passive immunization [108], and DeMattos et 
al. showed the same phenomenon in PDAPP mice [109]. Further studies into the 
appearance of microhemorrhages revealed a time-dependent increase in vascular 
amyloid deposition and the number of microhemorrhages, as well as an 
association of the microhemorrhages with these vascular deposits [109-111].  
Despite the observance of cerebrovascular pathologies in association with 
passive immunization of transgenic mice, successes in amyloid clearance and 
improved cognition spurred a number of clinical trials. The most promising antibody 
to enter clinical trials was bapineuzumab. Bapineuzumab is a humanized 
monoclonal IgG1 antibody that targets the N-terminal region of Ab and is thought 
to activate microglial phagocytosis and cytokine production [112]. In the Phase 1 
trial, participants received a single dose of 0.5, 1.5 or 5 mg/kg of bapineuzumab 
[112]. Notably, while the Phase 1 trial was not designed to measure effects on 
cognition, participants underwent cognitive testing before receiving their assigned 
dose and again 16 weeks later, allowing for the determination that bapineuzumab 
improved MMSE scores in those randomized to the 0.5 and 1.5 mg/kg groups 
[112]. Despite the fact that 3 of the 10 participants receiving 5 mg/kg of 
bapineuzumab developed vasogenic edema [112], the antibody progressed to a 
Phase 2 clinical trial. The Phase 2 trial included 234 participants with mild-to-
moderate AD randomized to bapineuzumab or placebo in one of four dose cohorts: 
0.15, 0.5, 1 or 2 mg/kg [113]. Participants received an infusion of their assigned 
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dose every 13 weeks for a total of 6 infusions and underwent final assessments at 
week 78 [113]. Unfortunately, no significant differences were observed in the 
primary efficacy analysis and 9.7% of bapineuzumab treated patients developed 
reversible vasogenic edema [113]. It may be noted that vasogenic edema was 
more frequent in ApoE4 carriers and those randomized to higher dose cohorts. 
Despite disappointing Phase 2 outcomes, a Phase 3 program was initiated. 
Importantly, because Phase 2 post-hoc exploratory efficacy by ApoE4 carrier 
status suggested a treatment response in noncarriers [114], the Phase 3 program 
consisted of separate clinical trials for E4 carriers and noncarriers [115]. 
Unfortunately, bapineuzumab failed to demonstrate therapeutic efficacy in both the 
carrier and noncarrier studies [115]. Furthermore, vasogenic edema was observed 
in 11.4% of participants heterozygous for E4, 27.3% of participants homozygous 
for E4, 14.2% of noncarriers randomized to 2.0 mg/kg, 9.4% of noncarriers 
randomized to 1.0 mg/kg, and 4.2% of participants randomized to 0.5 mg/kg of 
bapineuzumab [115].  
 The magnetic resonance imaging (MRI) abnormalities observed in the 
bapineuzumab trials, vasogenic edema and microhemorrhages, have since been 
associated with other amyloid modifying therapies. As a result, these abnormalities 
are now collectively referred to as amyloid-related imaging abnormalities, or ARIA 
[116]. ARIA-E refers to MRI signal alterations thought to represent vasogenic 
edema, while ARIA-H refers to alterations believed to be attributable to 
microhemorrhage and/or hemosiderosis [116]. ARIA-E is typically observed as a 
transient hyperintensity on FLAIR imaging and, at the cellular level, is thought to 
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represent an increase in extracellular fluid volume due to enhanced permeability 
of the brain capillaries [116]. By contrast, ARIA-H manifests as a low-intensity 
signal on T2* MRI or susceptibility-weighted imaging (SWI) and is thought to 
represent iron deposits indicative of a small leakage of blood from a vessel into the 
adjacent parenchyma (microhemorrhage) or subarachnoid space (superficial 
siderosis) [116].  To date, there is limited information regarding the relationship 
between ARIA-E and ARIA-H, however, their relation to dose in the bapineuzumab 
trials suggests ARIA may arise due to enhanced clearance of parenchymal 
amyloid [41, 44]. Hypotheses suggest the rapid movement of amyloid from the 
parenchyma into the perivascular space creates a drainage backup resulting in 
excess fluid shifts and vasogenic edema. Hypotheses also suggest that extraction 
of amyloid from the vasculature might result in enhanced permeability and fragility 
of brain capillaries. Assuming vessel wall integrity is sufficiently compromised, this 
proposed mechanism could explain the increased incidence of microhemorrhages 
following the administration of amyloid-modifying therapies.   
 The aforementioned hypotheses relate to those proposed for the 
mechanism by which anti-Ab antibodies clear amyloid from the brain. The first 
hypothesis centers on the traditional role of an antibody to opsonize antigens and 
induce phagocytosis and complement activation [117]. More specifically, this 
hypothesis suggests that anti-Ab antibodies bind to Ab, after which the Fc portion 
of the antibody binds the Fcg-receptor (FcgR) on microglia thereby inducing 
phagocytosis of amyloid. As previously discussed, experimental models of AD and 
observations from clinical trials have provided evidence that FcgR-induced 
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phagocytosis is largely responsible for amyloid clearance following 
immunotherapy [118]. Granted, due to the adverse events that accompany 
immunotherapy, a number of Ab antibodies with Fc modifications have been 
developed and are currently in trials. An alternative hypothesis, known as the 
“peripheral sink” mechanism, negates the assumption that anti-Ab antibodies cross 
the BBB [119]. This mechanism instead proposes that antibodies clear Ab from the 
blood, in turn generating a concentration gradient that favors exportation of Ab 
from the brain into the blood [119]. A third proposed mechanism suggests that anti-
Ab antibodies modify the secondary structure of Ab monomers making them less 
prone to aggregate into oligomeric or fibrillogenic forms [120]. Irrespective of their 
differences, it is unlikely that these three mechanisms are mutually exclusive. 
Rather, antibodies may use each of these mechanisms to varying degrees, and 
utilization likely depends on the specific binding sites and isotype of each antibody 
[118, 121].  
 Holistic interpretation of these data yields only one conclusion: it remains 
unclear whether microglial function in AD is beneficial but insufficient, whether 
microglia simply lose their efficacy, or whether microglia become detrimental 
throughout the course of disease progression. It is likely that analyzing bulk cell 
populations based on a subset of surface markers has contributed to conflicting 
reports regarding the role of microglia in AD. The recent advent of single-cell 
genomics has enabled unbiased characterization of immune cell types and states, 
in turn permitting the identification of new markers, pathways, and regulatory 
factors. A landmark study published by Keren-Shaul et al. in 2017 used single-cell 
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genomics to identify a new microglia phenotype associated with restricting 
neuroinflammation [122]. This study identified a subset of microglia that express 
both microglial genes (Cst3 and Hexb) and a unique signature of genes associated 
with lipid metabolism and phagocytosis (ApoE, Lpl, and Cst7) [122]. Notably, 
microglia possessing this phenotypic signature were observed in only in 5xFAD 
mice and therefore were defined as disease-associated microglia (DAM). 
Additionally, this study revealed that DAM are spatially associated with amyloid 
pathology and display an enhanced phagocytic capacity. In fact, genes expressed 
by DAM throughout disease progression revealed elevated lipid metabolism 
pathways as well as enhanced phagocytic genes, corresponding to the need for 
plaque clearance [122]. Interestingly, DAM were found to be regulated by the 
immunoreceptor TREM2 and its associated adaptor protein DAP12. TREM2 and 
DAP12 are known to form a signaling complex that may enhance phagocytosis 
and participate in the suppression of the inflammatory response by repressing 
microglia-mediated cytokine production [123]. Finally, activation of DAM was 
shown to occur via two sequential, but distinct phases. The first phase was shown 
to be TREM2-independent whereas the second phase involving the induction of 
lipid metabolism and phagocytic pathways (via increased expression of Lpl, Cst7, 
and CD9) requires TREM2 [122]. Importantly, the transition from homeostatic to 
fully activated DAM does not occur in the absence of TREM2, which ultimately 
supports the observation that the absence of TREM2 in late, but not early, AD 
exacerbates pathology [122, 123]. Therefore, it is possible the genes expressed 
by DAM are necessary to enhance phagocytosis and clear amyloid, but that 
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activation of DAM may occur relatively late in the disease. Genes expressed by 
homeostatic microglia, stage 1 DAM (TREM2-independent) and stage 2 DAM 
(TREM2-dependent) are outlined in Figure 1.3.  
 
TREM2 
 Triggering receptor expressed on myeloid cells-2 (TREM2) is a single-pass 
transmembrane protein expressed in cells of myeloid origin such as bone marrow 
and monocyte-derived macrophages and osteoclasts. Importantly, TREM2 is also 
expressed in the brain exclusively by microglia. Support for this claim arises from 
several in vitro studies showing primary cultured microglia express TREM2 as well 
as numerous in vivo studies demonstrating TREM2 expression in mouse microglia 
[124-132]. To date, TREM2 has been proposed to bind a variety of ligands 
including lipids, lipoproteins, and ligands associated with damage- or pathogen-
related molecular patterns [133]. Lipids have been shown to activate TREM2 
signaling both as components of a cellular membrane and as components of a 
lipoprotein complex [134]. More specifically, studies have shown that both lipidated 
and non-lipidated APOE binds the extracellular region of TREM2 in vitro and that 
TREM2 appears to have no preference in APOE isoform [135-137]. Moreover, Yeh 
et al. showed that TREM2 also associates with other lipidated apolipoproteins, 
specifically APOA1, APOB, and APOJ [137]. Additional ligands for TREM2 include 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), heparin sulfate 
proteoglycans and other negatively charged lipids [137-141].  
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Because TREM2 has a short cytoplasmic tail, it requires aid from its 
associated intracellular adaptor protein (DAP12) to mediate its signaling functions. 
Ligand binding to TREM2 results in the phosphorylation of DAP12 and subsequent 
recruitment of spleen tyrosine kinase (SYK) [142, 143]. SYK activation, in turn, 
activates a number of signaling cascades that ultimately induce Ca2+ mobilization, 
regulate phagocytosis, inhibit inflammatory signaling and promote cell survival 
(Figure 1.2) [142, 143].    
 Much of what we know about the genetics of TREM2 can be attributed to 
an autosomal recessive form of early-onset dementia known as Nasu-Hakola 
Disease (NHD). NHD is characterized clinically by bone cysts and fractures, 
neuropsychiatric symptoms, and importantly, presenile dementia [144-146]. 
Moreover, patients suffering NHD also experience axonal degeneration, white 
matter damage, and cortical atrophy accompanied by microglia and astrocyte 
activation [147-149]. Paloneva and colleagues were the first to link TREM2 
variants with NHD [150], and it has since been verified that homozygous 
expression of TREM2 variants causes NHD. TREM2 variants have recently been 
identified as risk factors for LOAD, and are now known to confer similar risk for 
LOAD as one copy of ApoE4 [151-153].  
 In 2013, two genome-wide association studies (GWAS) revealed that 
heterozygous expression of the TREM2 R47H and D87N variants were 
significantly associated with LOAD risk [154, 155]. Numerous studies have since 
replicated the association of these TREM2 variants with LOAD [156-161], one of 
which validated the R47H variant in neuropathologically confirmed cases [162]. 
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Additional TREM2 variants (R62H, L211P, T96K, and H157Y) have also been 
consistently shown to enhance LOAD risk [163-165]. Unlike variants causative of 
NHD which reduce TREM2 expression on the cell surface, LOAD-associated 
variants of TREM2 have been shown to impair the efficiency of TREM2 signaling, 
influence ligand affinity, and diminish phagocytic capacity.  
In 2016, two groups independently demonstrated that cells expressing the 
TREM2 variants R47H and R62H displayed impaired TREM2 signaling [138, 166]. 
Multiple groups also showed that the R47H, R62H, and D87N variants display 
decreased binding affinity between ApoE and TREM2 [135, 137, 141]. 
Furthermore, the R47H and R62H variants have been shown to exhibit decreased 
binding affinity between TREM2 and proteoglycans of the cell surface, whereas 
the T96K variant was shown to enhance this affinity [141]. The rarity of the T96K 
variant makes it difficult for scientists to determine its impact on AD risk, however, 
the ability of TREM2 variants to enhance or impair function suggests altered 
TREM2 homeostasis has neurodegenerative consequences [134]. In 2016 Kober 
et al. suggested potential structure-function mechanisms for the differing effects of 
LOAD-associated TREM2 variants [141]. This work established that the R47H and 
R62H variants are located within the extracellular, basic region of TREM2 likely 
important for its association with negatively charged ligands [141]. Variants within 
this basic region are predicted to decrease the binding affinity of TREM2 for a 
number of ligands. Interesting, the T96K variant was identified as being adjacent 
to this basic region and is therefore predicted to extend the site of the basic patch, 
subsequently enhancing ligand binding to TREM2 [141]. Expression of R47H in 
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Hek293 cells was shown to modestly decrease phagocytic capacity [167], and 
microglia from TREM2 knock-out mice have been shown to exhibit reduced uptake 
of APOJ, LDL, and Ab1-42 [137]. Importantly, despite their structural diversity, 
almost all of the TREM2 variants identified have been suggested to confer loss of 
function through different mechanisms.  
 To date, several laboratories have assessed whether partial or complete 
loss of TREM2 function contributes to Ab deposition or Ab-associated microglial 
activation and phagocytosis. Notably, studies have consistently shown that 
TREM2 deficiency results in a strong reduction in Ab-associated microgliosis, 
possibly due to an impaired transition of homeostatic microglia to DAM (Figure 
1.3). While this supports the notion that loss of TREM2 function is detrimental, 
there is no evidence that TREM2 gain of function would be beneficial.  
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Figure 1.1: Amyloid Cascade Hypothesis. 
The amyloid cascade hypothesis suggests that alterations in Ab metabolism lead 
to the oligomerization and deposition of Ab. Ab induced toxicity is then 
hypothesized to result in a number of cellular disturbances, subsequent 
hyperphosphorylation of tau, synaptic dysfunction, and neuronal death.     
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Figure 1.2: TREM2 Signaling Cascade. 
Upon ligand binding to TREM2, tyrosine residues on the immunoreceptor tyrosine-
based activation motif (ITAM) region of DAP12 are phosphorylated and SYK is 
recruited. Activation of SYK initiates a number of signaling cascades that ultimately 
enhance the survival, proliferation, and phagocytic capacity of microglia.  
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Figure 1.3: Gene Expression in DAM Microglia.  
In the presence of Ab, homeostatic microglia transition into stage 1 DAM via 
TREM2-independent mechanisms. Conversely, the transition from stage 1 to 
stage 2 DAM requires the presence of TREM2. Key genes expressed in each 
stage are listed. Red arrows indicate the up-regulation of genes in the specific 
stage, whereas green arrows represent the down-regulation.  
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Abstract 
Triggering receptor expressed on myeloid cells-2 (TREM2) is a lipid and 
lipoprotein binding receptor expressed by activated innate immune cells. 
Homozygous TREM2 loss of function mutations cause early onset progressive 
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presenile dementia while heterozygous, function-reducing point mutations triple 
the risk of Alzheimer’s disease (AD). This is due in part to a reduction in microglia 
survival, proliferation, chemotaxis and phagocytic activity. Although human genetic 
findings support the notion that loss of TREM2 function exacerbates 
neurodegeneration, it is not clear whether activation of TREM2 in a disease state 
would result in therapeutic benefits. Here we show that chronic activation of 
TREM2, in the 5XFAD mouse model of AD, leads to reversal of AD gene 
expression signature, recruitment of microglia, decreased amyloid deposition, and 
improvement in spatial learning and novel object recognition memory. These 
findings indicate that TREM2 activators may be effective for the treatment of AD 
and possibly other neurodegenerative disorders. 
 
Significance Statement 
TREM2 is a receptor expressed on myeloid cells including microglia and 
monocytes. Mutations in TREM2, while rare, have been shown to significantly 
increase an individual’s risk for developing AD. Much of the literature supports the 
hypothesis that the TREM2 mutation increases AD risk through a loss-of-function 
of the receptor. Based on this hypothesis, we have chosen to explore therapeutic 
targeting of TREM2 as a treatment for AD with the goal of agonizing TREM2 and 
activating its signaling. An antibody, AL-002a, agonizes TREM2 and results in 
clustering of microglia around plaques, clearance of amyloid plaques, and 
improved cognition. These data suggest targeting TREM2 is a feasible therapeutic 
approach for the treatment of AD.  
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Introduction  
 
The triggering receptor expressed on myeloid cells 2 (TREM2) is a single 
transmembrane receptor expressed on the surface of microglia, and other myeloid 
cells, that binds damaged DNA, amyloid beta (Ab), lipids, glycolipids, lipoproteins 
and apolipoproteins including ApoE and clusterin/ApoJ [123, 135-137]. Ligand 
binding leads to TREM2 co-clustering with the immunoreceptor tyrosine-based 
activation motif (ITAM) containing transmembrane protein TYROBP/DAP12 and to 
tyrosine phosphorylation of DAP12 by Src family kinases. Phosphorylated DAP12 
in turn recruits tyrosine kinase Syk leading to activation of downstream signaling 
events, including intracellular Ca2+,  flux [143], activation of extracellular signal-
regulated kinases (ERK) and of phosphoinositide 3-kinase (PI3K) [168], and 
nuclear translocation of the transcription factor Nuclear Factor of Activated T cells 
(NFAT) [123]. The resulting changes in gene expression and post transcriptional 
modifications  induce an increased cellular response to colony stimulating factor 
[169], actin reorganization [143], process extension [170], cytokine release [171, 
172], survival [173, 174], proliferation [169], migration [175] and phagocytosis [176] 
in TREM2 expressing dendritic cells (DC) [172], tissue macrophages [177], 
osteoclasts [178] and microglia [179].  People with homozygous loss of function 
mutations in TREM2 [180] invariably develop polycystic lipomembranous 
osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as 
Nasu-Hakola disease (NHD), which manifests as early onset presenile dementia 
with frequent bone cysts [181], or as frontotemporal dementia (FTD) [154] with 
seizures and corpus callosum atrophy. Heterozygous TREM2 point mutations, 
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which reduce either ligand binding [137] or cell surface expression [167], are 
associated with a reduction in the number of microglia surrounding amyloid 
plaques, microglial inability to compact beta-amyloid deposits and form a barrier 
between plaques and neurons [170], an increase in the number of phospho- tau 
positive, dystrophic neurites [182] as well as increased tau in cerebrospinal fluid 
[183]. Heterozygous mutations also double the rate of brain atrophy [182, 184], 
triple the risk of AD [151, 155] and decrease the age of AD onset by 3-6 years 
[185].  
TREM2 homozygous (TREM2-/-) or heterozygous (TREM2+/-) deficient 
wildtype (WT) or AD mice also display multiple microglia pathologies, including 
increased apoptotic cell death, reduced number of microglia, inability to coalesce 
around and compact beta amyloid plaques [186], nonreactive cell morphology, 
abnormal AD gene expression signature [187], age dependent inability to reduce 
total Ab plaque load [188] and an inability to support Ab antibody-mediated beta 
amyloid plaque clearance [189]. TREM2 (-/-) microglia fail to fully activate into 
phagocytic, disease-associated microglia and to express the associated gene 
signature in AD mice [122]. Although, human genetics indicate that loss of TREM2 
function is detrimental, there is no evidence that TREM2 gain of function would be 
beneficial. TREM2 pathology, like beta amyloid pathology [190], may begin 
decades before clinical findings, rendering intervention in diagnosed AD patients 
ineffective. Likewise, activation of TREM2 may result in indiscriminate and harmful 
stimulation of microglia and other innate immune cells.  To determine the viability 
of TREM2 activation as a therapeutic strategy, we sought to identify and 
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characterize an agonistic TREM2 antibody and test its efficacy and mechanism of 
action in an aggressive mouse model of AD. 
 
Materials and Methods 
 
Animals. 5XFAD transgenic mice overexpressing the K670N/M671L (Swedish), 
I716V (Florida), and V717I (London) mutations in human APP (695), as well as 
M146L and L286V mutations in human PS1 (28-30) [61] were aged to 3.5 months 
at Taconic and transferred to University of Kentucky. The study was approved by 
the University of Kentucky Institutional Animal Care and Use Committee and 
conformed to the National Institutes of Health Guide for the Care and Use of 
Animals in Research. All studies were performed blinded. Alector provided the 
antibodies coded, and the mice were also coded and randomized into each group. 
Only upon completion of the data analysis were the groups unblinded.  
 
Murine macrophages. Murine bone marrow precursor cells from TREM2-KO and 
TREM2-WT (Alector colony) were obtained by flushing tibial and femoral marrow 
cells with cold PBS containing 2% FBS. Red blood cells were lysed using ACK 
lysing buffer, washed twice with 2% FBS/PBS and re-suspended in complete 
media (RPMI, 10% FBS, Pen/Strep, L-glutamine, non-essential amino acid) with 
50ng/mL murine M-CSF (m-MCSF) to differentiate macrophages for 6 days. For 
FACS analysis of AL-002abinding to BMM’s, cells were washed in FACS buffer 
(PBS + 2% FBS) and incubated with either AL-002a, rat anti-TREM2 (R&D 
Systems) as a positive control, or murine IgG1 isotype (BD Biosciences) as a 
negative control in FACS buffer for one hour on ice. Cells were washed thrice in 
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FACS buffer and spun. Goat anti-mouse APC conjugated secondary antibody was 
added (BD Biosciences, 1:100) in FACS buffer and cells were incubated on ice for 
30 minutes. Cells were again washed as before, re-suspended in FACS buffer and 
analyzed on a BD Canto Flow Cytometer. 
 
Biochemistry. Before stimulation, BMM were starved for 4h in 1% serum RPMI. 5 
× 106 cells for Syk immunoprecipitation or 15 × 106 cells for TREM2 
immunoprecipitation were then incubated in ice for 15 min with 1µg of antibody for 
1 ×106 cells. Cells were then washed and incubated at 37°C for the indicated 
period of time in the presence of goat anti-human IgG or goat-anti mouse IgG 
(1.5µg for 1 ×106 cells). After stimulation, cells were lysed with lysis buffer (1% v/v 
NP-40%, 50 Mm Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1.5 mM MgCl2, 
10% glycerol, plus protease and phosphatase inhibitors) and immunoprecipitated 
with anti-Syk antibody (N-19, Santa Cruz). For receptor immunoprecipitation cells 
were lysed with 1% n-Dodecyl-β-D-Maltoside and immunoprecipiated with anti-
TREM2 (R&D system) or isotype control. Precipitated proteins were fractionated 
by SDS-PAGE, transferred to PVDF membranes and probed with anti-
phosphotyrosine Ab (4G10, Millipore) and anti-Dap12 antibody (Cell Signaling). To 
confirm that all substrates were adequately immunoprecipitated, immunoblots 
were reprobed with anti-Syk antibody (Abcam, for BMM). Because anti-TREM2 
antibody does not detect TREM2 in immunoblotting, each cell lysate used for 
TREM2 immunoprecipitations contained equal amount of proteins with a control 
antibody (anti-actin, Santa Cruz). 
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Intracranial Administration. Twenty-four 5-month old male 5XFAD mice were 
assigned to one of two injection groups: MOPC (control antibody; mIgG1 isotype; 
Bioxcell), or AL-002a (mIgG1isotype; Alector). On the day of surgery mice were 
weighed, anesthetized with isoflurane, and placed in a stereotaxic apparatus 
(51733D digital dual manipulator mouse stereotaxic frame; Stoelting). A mid-
sagittal incision was made to expose the cranium and four burr holes were drilled 
with a dental drill mounted in the stereotaxic frame over the frontal cortex and 
hippocampus to the following coordinates: frontal cortex, anteroposterior, +2.0 
mm, lateral ± 2.0 mm; hippocampus, anteroposterior - 2.7 mm; lateral, ± 2.5 mm, 
all taken from bregma. A 26-gauge needle attached to a 10 mL Hamilton syringe 
containing the solution to be injected was lowered 3.0 mm ventral to bregma, and 
a 2 L injection was made over a 2 min period. Antibodies were diluted to a final 
concentration of 5 mg/kg in 1X PBS. The incision was cleaned and closed with 
surgical staples. Buprenophine hydrochloride diluted to 0.015 mg/mL was 
intraperitoneally injected immediately post-surgery at 0.1 mg/kg dose per body 
weight. Animals received subsequent doses every 12 hours until sacrifice. Tissue 
was harvested 72 hours post injection.  
 
Systemic administration. The two antibodies (MOPC; mIgG1 isotype; Alector, LLC, 
or AL-002a; mIgG1isotype; Alector, LLC) were diluted to a final concentration of 
5mg/mL in 1XPBS. Twenty-four 5XFAD (N=12 per antibody group) and 15 wildtype 
mice (N=8 in AL-002agroup and N=7 in MOPC group) aged 4 months received AL-
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002a, or MOPC control antibody at a dose of 50 mg/kg/week administered 
intraperitoneally for 14 weeks. Mice were tested in our behavioral paradigms 
during the 2 weeks prior to sacrifice. Mice were euthanized and tissue was 
harvested 24 hours after the last injection.  
 
Tissue processing. Mice were perfused intracardially with 25mL of normal saline. 
Brains were rapidly removed and bisected in the mid-sagittal plane. The left half 
was immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours. The 
right half was dissected into cerebral cortex (anterior and posterior), hippocampus, 
striatum, and cerebellum. The dissected pieces were flash frozen in liquid nitrogen, 
and stored at -80°C. The left hemibrain was passed through a series of 10, 20, and 
30% sucrose solutions as cryoprotection and 25µm frozen horizontal sections 
were collected using a sliding microtome and stored floating in PBS containing 
sodium azide at 4°C. Sections were collected sequentially for the intracranial study 
and serially for the intraperitoneal study. 
 
Histology and immunohistochemistry. For the intracranial study, six sections 
spaced 300µm spanning the estimated injection site were initially mounted and 
stained by mouse IgG to identify the injection site. For all subsequent histology 
and immunohistochemistry on the intracranial study, six sections spanning the 
injection site, spaced ~100 µm apart, were selected and analyzed. For the 
systemic administration study, serial horizontal sections spaced 600µm apart were 
selected for histology and immunohistochemistry. Sections were mounted onto 
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slides and stained for Congo red as described previously. Free-floating 
immunohistochemistry for CD11b (rat monoclonal; AbD Serotec) and Ab (rabbit 
polyclonal Ab1–16; Invitrogen). Briefly, sections were quenched for endogenous 
peroxidase, blocked and permeabilized. They were then incubated overnight in 
primary antibody at 4°C (Ab 1:3000, CD11b 1:1000). After washing, sections were 
incubated for 2 hours in the appropriate biotinylated secondary antibody (goat anti-
rabbit IgG for Aβ, goat anti-rat for CD11b, all 1:3000; Vector Laboratories, 
Burlingame, CA, USA). Sections were then washed and incubated for 1 hour in 
ABC. DAB with (CD11b) and without (Ab) nickel was used for color development. 
Stained sections were mounted, air dried overnight, dehydrated, and coverslipped 
in DPX (Electron Microscopy Sciences, Hatfield, PA, USA). Immunohistochemical 
analysis was performed by measuring percent area occupied by positive stain 
using the Nikon Elements BR image analysis system (Melville, NY, USA) as 
described previously (32). 
 
Microglial clustering around plaques: We performed double label of sections to 
detect plaques and microglia using CD11b immunohistochemistry counter-stained 
with Congo red. Using a macro developed in our image analysis software, eight 
plaques of a defined size per section were identified by the software in each of the 
frontal cortex and hippocampus. A ring was projected around the perimeter of the 
plaque that was 2 cell bodies wide (15µm). The blinded analyst then clicked on 
each CD11b-positive cell body within the perimeter to determine the numbers of 
microglia surrounding that plaque. Between six and eight sections per mouse were 
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analyzed in this way. Mean number of microglia per plaque were calculated for 
each animal before being analyzed statistically as described below. 
 
Quantitative real-time reverse transcription (RT)-PCR. RNA was extracted from left 
hippocampus using the EZNA RNA II Purification System (Omega Bio-Tek) 
according to the manufacturer’s instructions. RNA was quantified using the 
BioSpec Nano spectrophotometer (Shimadzu) and cDNA was reverse transcribed 
using the cDNA High Capacity kit (Applied Biosystems) according to the 
manufacturer’s instructions. Real-time RT-PCR was performed using the 384-well 
microfluidic card custom TaqMan assays containing TaqMan Gene Expression 
probes for our genes of interest (Applied Biosystems, Invitrogen). All gene 
expression data were normalized to 18S rRNA expression. Fold change was 
determined using the DDCt method.  
 
Radial Arm Water Maze. After 12 weeks of treatment, mice were subject to a two-
day radial arm water maze (RAWM) paradigm, as previously described (33). On 
day one, 15 trials were run in two blocks of 6 followed by the last three trials. A 
cohort of 4 mice was run sequentially for each block (i.e., each of 4 mice undergo 
trial one, then the same mice undergo trial two, etc.). After each block, a second 
cohort of mice was run, permitting an extended rest period before mice were 
exposed to the next block trials (extra wait time was added to the end of the block 
with three trials to make the rest period similar throughout the behavior). The goal 
arm was different for each mouse in a cohort to minimize odor cues. The start arm 
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was varied for each trial, with the goal arm remaining constant for a given individual 
for both days. For the first 11 trials, the platform was alternately visible then hidden 
(hidden for the last 4 of 15 trials). On day two, the mice were run in exactly the 
same manner as day one except that the platform remained hidden for all 15 trials. 
The number of errors (incorrect arm entries) was measured in a one-minute time 
frame. As standard practice, mice failing to make an arm choice in 15 seconds are 
assigned one error. In order to minimize the influence of individual trial variability, 
each mouse's errors for 3 consecutive trials were averaged producing 5 data points 
(termed “blocks”) for each day, which were then analyzed statistically by ANOVA 
using the JMP statistical analysis program (SAS). 
 
Novel Object Recognition. Following the RAWM, the novel object recognition task 
was performed. During the habituation phase, each mouse was gently placed into 
a square box (50 × 50 × 15 cm, length × width × height) for 30 min per day for 1 
day without any objects. During the training phase, two identical objects, A1 and 
A2, were placed parallel to and near one wall of the square box. Each mouse was 
placed singly in the box and allowed to explore the objects for 5 min. Exploratory 
behavior was defined as directing the nose at the object at a distance of less than 
2 cm and/or touching the object with the nose. The mouse was then returned to its 
home cage with a 1 h inter-trial interval. Both objects were replaced; one being a 
familiar object (A1) and the other a novel object (B). The mouse was returned to 
the box and allowed to explore the objects for 5 min during the test phase. Novel 
and familiar objects were alternated between the left and right positions to reduce 
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potential bias toward a particular location. The objects and the box were cleaned 
with ethanol (10%) after each individual trial to eliminate olfactory cues. The 
exploration time (s) for each object in the trials was recorded. The preferential 
index (PI) was calculated as [time spent exploring novel object/total exploration 
time].  
 
Analysis. Data are presented as mean± SEM. Statistical analysis was performed 
using the JMP statistical analysis program (SAS). Statistical significance was 
assigned where the p value was lower than 0.05. One-way ANOVA and two-way 
ANOVA were used, where appropriate, to detect treatment differences and 
differences within treatment groups along the time course. Student’s t Test was 
used for post-hoc comparisons.  Mice were genotyped for the retinal degeneration 
(rd) mutation postmortem. We found that there were six total mice homozygous for 
the rd mutation. Five of these were wildtype mice, and one was a 5XFAD in the 
AL-002a group. These mice were included for histological analysis but excluded 
for the radial arm water maze and novel object recognition data analysis.  
 
Results  
 
AL-002a is a mouse IgG1 antibody that has been generated to recognize 
the extracellular portion of the TREM2 receptor. AL-002aspecifically recognizes 
TREM2 on WT bone marrow derived macrophages (BMM), while binding is 
reduced to isotype control levels in cells derived from TREM2 KO mice (Figure 
2.1A). In vitro, AL-002a activates the TREM2 signaling pathway. Treatment of 
peripheral bone marrow derived macrophages (BMM) with AL-002a resulted in 
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DAP12 and Syk phosphorylation, indicating activation of the TREM2 signaling 
pathway. Importantly, when these studies were repeated using BMM from TREM2-
/- mice, there was no DAP12 or Syk response, indicating specific action through 
TREM2 (Figure 2.1B and 2.1C).  
Intracranial Administration of AL-002a 
To determine the effects of AL-002a in the brain, we performed stereotaxic 
surgery to inject 2µl of 5mg/mL AL-002a or the isotype control antibody, MOPC, 
into the frontal cortex and hippocampus bilaterally (N=12 / antibody). In previous 
studies working with anti-Ab antibodies, a time-course revealed the optimal time-
point to examine the brain post-injection is 72 hours. Using that study as our guide, 
mice survived for 72 hours and, upon euthanasia, the right hippocampus was flash 
frozen and RNA was extracted to perform gene expression analysis. The left 
hemisphere was immersion fixed in paraformaldehyde and processed for 
histology. Since we hypothesized that TREM2 activation would modulate the 
immune response in the brain, we used RNA extracted from the hippocampus to 
perform real-time RT-PCR for inflammatory genes. The data are shown as a fold 
change from the 5XFAD mice receiving control IgG (Figure 2.2A). We found at 72 
hours there was a significant increase in both pro-inflammatory (IL1b, TNFa, 
CCL3, CCL5, CCR2, CXCL10, Gata3, Rorc) and anti-inflammatory (YM1, CD86) 
mediators as a result of AL-002a treatment compared to mice injected with control 
antibody. To determine microglial activation, we performed immunohistochemistry 
for CD11b, which labels both activated and resting microglia. Activated microglia 
express greater levels of CD11b and cover a greater area due to the enlarged cell 
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bodies and thickened processes associated with activation. We found a significant 
increase in CD11b immunoreactivity in 5XFAD and WT mice treated with a TREM2 
antibody compared to the control treated mice, suggestive of microglial activation 
in the regions injected with AL-002a compared to the same regions injected with 
control antibody (Figure 2.2B).  
Deposition of Ab occurs as both diffuse and compact plaques with the vast 
majority of Ab deposited being diffuse. Immunohistochemistry for total Ab, which 
detects both compact and diffuse deposits, in 5XFAD transgenic mice receiving 
control antibody showed a typical staining pattern for mice of this age (Figure 2.2C) 
[61]. Mice receiving the AL-002a antibody showed significant reductions in total Ab 
immunohistochemistry in both the frontal cortex and hippocampus compared to 
mice receiving control antibody. In the frontal cortex, Ab deposition was reduced 
by 50% and in the hippocampus Ab deposition was reduced by 35-40% (Figure 
2.2C). The histological dye Congo red labels only compact amyloid deposits and 
stains approximately 5% of the material stained by immunohistochemistry for total 
Ab. As shown in Figure 2.2D, the distribution of Congophillic deposits resembles 
that observed for total Ab. Mice receiving the AL-002a antibody showed significant 
reductions in compact amyloid deposits in both the frontal cortex and hippocampus 
compared to those mice receiving the control antibody (Figure 2.2D).  
Systemic Administration of AL-002a 
Given the positive outcomes of our stereotaxic studies above, we moved to 
perform a chronic, systemic administration study. Twenty-four male 5XFAD and 
fifteen wildtype mice aged 4 months received AL-002a (N=12 5XFAD, N=8 WT) or 
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control antibody (N=12 5XFAD, N=7 WT) at a dose of 50 mg/kg/week administered 
intraperitoneally for 14 weeks. Mice were tested in our behavioral paradigms 
during the 2 weeks prior to sacrifice. The radial-arm water maze (RAWM) is a 
behavioral test that reliably detects spatial learning and memory deficits in aged 
transgenic mice [68]. 5XFAD transgenic mice were tested after 12 weeks of 
treatment with AL-002a or MOPC (control antibody). Included in the task were age-
matched non-transgenic littermate mice treated with AL-002a or control antibody 
(these mice were grouped due to no significant difference between the two 
treatments in the non-transgenic mice). We found that the 5XFAD transgenic mice 
receiving control antibody were significantly impaired when compared with the 
non-transgenic mice (Figure 2.3A). However, 5XFAD transgenic mice treated with 
AL-002a performed significantly better than control treated 5XFAD transgenic mice 
(Figure 2.3A). The AL-002a-treated 5XFAD mice were indistinguishable from the 
WT mice at the end of the second day of testing, averaging less than one error, 
our criterion for stable acquisition of this task (Figure 2.3A). In examining the AL-
002a effect at the end of the second day of testing, we found that there was a 
significant reduction in the number of errors in the 5XFAD mice receiving AL-002a 
compared to 5XFAD receiving control antibody (Figure 2.3B).  
One week after completion of the RAWM, the novel object recognition 
(NOR) task was performed to investigate recognition memory [191]. We found that 
5XFAD transgenic mice treated with the control antibody spent significantly more 
time on the familiar object compared to the 5XFAD mice treated with AL-002a 
(Figure 2.3C). Additionally, AL-002a treated 5XFAD transgenic mice exhibited 
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significantly increased explorative behavior as compared to the control antibody 
treated 5XFAD transgenic mice (Figure 2.3C).  
Immunohistochemistry detecting total Ab, both compact and diffuse 
deposits, in the 5XFAD transgenic mice treated with control antibody showed a 
typical staining pattern for mice of this age (Figure 2.4D) [61]. The 5XFAD mice 
treated with AL-002a showed significant reductions in total Ab 
immunohistochemistry in both the frontal cortex and hippocampus compared to 
control treatment (Figure 2.3D). In the frontal cortex, Ab deposition was reduced 
by 40% and in the hippocampus Ab deposition was reduced by 35% (Figure 2.3D). 
The distribution of Congophillic deposits resemble that observed for total Ab 
(Figure 2.3E). The 5XFAD mice treated with AL-002a showed significant 
reductions in compact amyloid deposits in only the hippocampus with no significant 
change in the frontal cortex (Figure 2.3E).  
To characterize the neuroinflammatory response to AL-002a, we isolated 
RNA from the right hippocampus and performed real-time RT-PCR for genes 
relatively specific for inflammatory and anti-inflammatory properties. The data in 
Figure 2.4A are shown as a fold change from the 5XFAD mice treated with the 
control antibody. We found after 14 weeks of treatment there was a significant 
increase in both pro-inflammatory (IL1b, TNFa, CCL2, CXCL10, Gata3, Rorc) and 
anti-inflammatory phenotypic markers (YM1 and IL1Rn) compared to control 
treated mice (Figure 2.4B). Immunohistochemistry detecting CD11b indicated a 
significant increase in microglial staining in 5XFAD mice treated with AL-002a 
compared to the 5XFAD mice treated with control antibody (Figure 2.4B). During 
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image processing, it was noted that there appeared to be more microglia 
associated with plaques in some mice as compared to others. Using an analysis 
method developed for this purpose, we calculated the mean number of microglial 
cells per plaque for each animal. We found significantly increased numbers of 
microglia associated with plaques in mice treated with AL-002a compared to mice 
treated with control antibody. The increase was approximately double the number 
of microglia in the frontal cortex and triple the number of microglia in the 
hippocampus per plaque.  
 
Discussion 
 
Therapeutic approaches to the treatment of AD continue to focus on the 
major pathological hallmarks of the disease: amyloid plaques and neurofibrillary 
tangles [192-194]. These two pathologies remain the requirements for diagnosis 
of AD. However, the explosion of genetic data has suggested that risk for sporadic 
AD is driven by several distinct pathways such as neuroinflammation, membrane 
turnover and storage, and lipid metabolism [195]. Of particular importance was the 
description that a mutation in the TREM2 gene significantly increases an 
individual’s risk of developing AD [151, 155]. While this mutation has low 
penetrance in the population, those who carry the TREM2 R47H loss of function 
mutation have a 4.5-fold increased risk of developing AD compared to those 
without the mutation. Our hypothesis in the current study was that targeting 
TREM2 with an antibody, thereby activating the receptor, would increase TREM2 
function leading to immune modulation, clearance of amyloid deposition, and 
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improved cognition without the need to directly target the Ab protein itself. To test 
this hypothesis, the antibody developed by Alector, AL-002a, was found to activate 
TREM2 signaling in vitro and activate immune responses in vivo, whether injected 
intracranially or systemically. AL-002a also activated microglial cells, increased 
clustering of microglia around the amyloid plaques, and ultimately resulted in 
reduced amyloid deposition and improved cognition (cognition was only examined 
in the systemic administration study).  
It is not unusual to find an association between microglial activation and 
amyloid reductions. As far back as 2000, lipopolysaccharide (LPS), the prototypical 
immune activator, was found to activate microglia and reduce amyloid deposition 
[196]. Anti-Ab antibodies also activate microglia and reduce amyloid deposition 
[105, 107]. It is interesting to compare and contrast the findings of AL-002a to an 
anti-Ab antibody treatment approach currently in clinical trials. We have previously 
shown that anti-Ab immunotherapy activates microglia [106, 107, 197], and alters 
neuroinflammatory gene expression [198], but we find a unique inflammatory 
signature with AL-002a as opposed to the anti-Ab antibody. AL-002a increased 
both pro-inflammatory and anti-inflammatory / repair gene expression, while anti-
Ab antibodies have only been shown to increase pro-inflammatory gene 
expression and, in some cases, decrease the anti-inflammatory gene expression. 
It is possible that the increase in gene expression by AL-002a represents a more 
homeostatic neuroinflammatory response with a more limited capacity to induce 
surrounding tissue damage while also ameliorating the amyloid deposition.  
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It is intriguing that we found immune-associated genes being expressed in 
different ways depending on whether AL-002a is administered intracranially or 
systemically. Following intracranial administration of AL-002a, we found almost 
every gene measured was increased compared to the age-matched 5XFAD mice 
receiving intracranial injection of control antibody. This likely reflects the acute 
response to the antibody and activation of TREM2. In contrast, following fourteen 
weeks of systemic administration, the chemokines CCL3, CCL5 and CCR2 were 
not significantly increased but IL1b and IL1Rn were significantly increased with 
systemic administration. Of note, activation of several genes by the AL-002a 
antibody indicate a novel mechanism of action relative to immunotherapy targeting 
Ab. CCR2 is a chemokine receptor expressed on microglia thought to mediate the 
accumulation of phagocytes at sites of inflammation [199]. CCL2 and CCL5 are 
chemokines that have been shown to increase the chemotaxis of microglia toward 
amyloid deposits [200]. The increased CCL2 and CCL5 expression, along with the 
increased CCR2 expression could be responsible, in part at least, to the increased 
clustering of microglia around the amyloid deposits seen in our systemic 
administration study. We also found increases in two key genes that are 
associated with T-cell differentiation into Th17 cells; Gata3 and Rorc [201]. While 
increased expression of IL1b  and TNFa are sometimes associated with tissue 
damage and neurodegeneration, in some settings, the increase in these pro-
inflammatory cytokines accompanies clearance of pathological proteins such as 
amyloid deposits [202, 203]. Anti-Ab antibodies have been shown to increase 
these cytokines [198], as has genetic deletion of IL-10 [204] and injection of LPS 
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[196, 205]. Additionally, reductions in these cytokines has been associated with 
worse cognitive outcomes and exacerbation of amyloid deposition as observed 
when IL10 is over-expressed [206], or when lithium is administered to mice, which 
enhances IL-10 signaling [207]. It is our hypothesis that the enhanced expression 
of inflammatory genes in the current setting is balanced by the YM1, IL1Rn, and 
CD86 expression, thereby limiting the capacity for tissue damage. Future studies 
will further examine this hypothesis.  
By using two distinct behavioral paradigms in the current study, we are 
confident in concluding that AL-002a significantly enhances cognition, or at the 
very least, prevents progression of cognitive decline, in the 5XFAD mouse model. 
The two-day radial arm water maze task was designed to test both working 
memory (the day 1 learning) and long-term spatial memory (day 1 to day 2 
retention). The novel object recognition task, as used in the current study, is a 
useful task to assess short-term memory. Both tasks have been shown to be 
heavily hippocampal dependent, but also have aspects of cortical involvement 
[208, 209]. In contrast to the radial arm water maze, the novel object recognition 
does not rely on motivation or reward, but simply on the innate exploratory 
behavior of a mouse. We found robust improvements in cognition with AL-002a 
systemic administration as detected in either the radial arm water maze task or the 
novel object recognition task.  
In summary, we show here that the therapeutic targeting of TREM2 using a 
TREM2-activating antibody leads to activation of microglia, recruitment of 
microglia to amyloid plaques, reduced amyloid deposition, and ultimately, 
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improved cognition. TREM2 deficient microglia fail to fully activate into phagocytic, 
disease-associated microglia and to express the associated gene signature in AD 
mice. Likewise, TREM2 deficient microglia fail to clear myelin debris. Our data 
support a critical role for TREM2 in microglial phagocytosis with increased 
microglial clustering at amyloid plaques and reductions in amyloid deposition using 
a TREM2-activating approach. We predict that activation of TREM2 through the 
use of antibodies like AL-002a will prove to be a novel, innovative therapeutic 
approach to the treatment of AD that will lack the adverse events observed with 
direct binding of Ab in the brain by anti-Ab antibodies.  
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Figure 2.1: AL-002a promoted TREM2-dependent DAP12 and Syk 
phosphorylation. Panel A shows that AL-002a binds to BMM derived from WT, 
but not TREM2 KO mice, as measured by FACS. A rat anti-TREM2 antibody 
from R&D Systems was used as a positive binding control and an isotype 
msIgG1 antibody as a negative control. Panel B: Following AL-002a stimulation, 
WT or Trem2-/- BMM were lysed and immunoprecipitated with TREM2 antibody. 
Protein was loaded on a SDS gel in unreduced conditions. Membranes were first 
blotted with anti-phosphotyrosine antibody and later stripped and blotted again 
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with anti-Dap12 antibody and anti-actin. Panel C: After AL-002a stimulation, WT 
or TREM2-/- BMM were lysed and immunoprecipitated with Syk antibody. 
Membranes were first blotted with anti-phosphotyrosine antibody and later 
stripped and blotted again with anti-Syk antibody.  
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Figure 2.2: Intracranial injection of AL-002a activates microglia and 
ameliorates amyloid deposition in 5XFAD mice. Panel A shows the RT-PCR 
data obtained from the right hippocampus of the injected mice. All data are 
shown as fold-change relative to the mean of the control antibody-injected mice. 
Data were analyzed using single, one-way ANOVA measures for each gene of 
interest, using a Bonferroni correction for multiple comparisons. Panel B shows 
the microglial activation (CD11b) in the hippocampus (images shown) and frontal 
 58 
cortex following intracranial injection of control antibody or AL-002a. Panel C 
shows the total Ab deposition in the hippocampus (images shown) and frontal 
cortex following intracranial injection of control antibody or AL-002a. Panel D 
shows Congo red labeling of compact amyloid deposits in the hippocampus 
(images shown) and frontal cortex following intracranial injection of control 
antibody or AL-002a. For all graphs, black bars represent AL-002a while grey 
bars represent control antibody. * indicates P<0.05, ** indicates P<0.01.  For 
images in B, C and D, magnification = 40X, scale bars shown = 120µm. 
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Figure 2.3: Systemic administration of AL-002a improves learning and 
memory and lowers amyloid deposition in 5XFAD mice. Panel A shows the 
radial-arm water maze data. Blocks 1-5 are day 1, blocks 6-10 are day 2. The 
black line is the learning curve of the 5XFAD mice receiving AL-002a, the grey 
line is the learning curve of the 5XFAD mice receiving control antibody, and the 
dashed line is the learning curve of the non-transgenic littermates receiving 
control or AL-002a (data was pooled due to lack of difference between the two 
treatment groups). Panel B shows a bar graph to illustrate the difference in 
number of errors made for the final block of trials (block 10). Panel C shows the 
bar graph for the novel object recognition data, where % exploration time with 
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novel object is shown. 50% exploration time would represent chance. Panel D 
shows the total Ab deposition in the hippocampus (images shown) and frontal 
cortex of control antibody or AL-002a. Panel E shows Congo red labeling of 
compact amyloid deposits in the hippocampus (images shown) and frontal cortex 
of control antibody or AL-002a. For all graphs, black bars are AL-002a, and grey 
bars are control antibody. * indicates P<0.05, ** indicates P<0.01. For images in 
B, C and D, magnification = 40X, scale bars shown = 120µm. 
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Figure 2.4: Neuroinflammatory changes are apparent following AL-002a 
treatment. Panel A shows RT-PCR data obtained from the right hippocampus. 
All data are shown as fold-change relative to the mean of the control antibody 
treated mice. Data were analyzed using single, one-way ANOVA measures for 
each gene of interest, using a Bonferroni correction for multiple comparisons. 
Panel B shows the microglial activation (CD11b) in the hippocampus (images 
shown) and frontal cortex of control antibody or AL-002a. Magnification = 40X, 
scale bar shown = 120µm. Panel C shows the microglial clustering around an 
amyloid plaque. Magnification = 400X, scale bar shown = 12.5µm. For all graphs, 
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black bars are AL-002a, and grey bars are control antibody. * indicates P<0.05, 
** indicates P<0.01.   
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Chapter 3 
Intracranial co-administration of TREM2 agonizing and anti-Ab antibodies 
does not further augment amyloid clearance in the 5XFAD model of AD 
despite unique neuroinflammatory responses.   
 
Abstract 
Alzheimer’s disease (AD) is the most common form of dementia, accounting 
for roughly 60% of dementia cases. To date, therapeutic approaches to the 
treatment of AD continue to focus on the major pathological hallmarks of the 
disease: extracellular amyloid plaques comprised of the Ab peptide and 
intracellular neurofibrillary tangles comprised of hyperphosphorylated tau protein. 
One of the most extensively characterized therapeutics for AD is anti-
Ab immunotherapy, which uses antibodies against Ab to promote its clearance 
from the brain via microglial Fcg-receptor (FcgR)-mediated phagocytosis. 
Numerous studies have confirmed the ability of anti-Ab immunotherapy to clear 
Ab and improve cognition in transgenic mouse models of AD. Loss-of-function 
mutations in the microglial TREM2 receptor have been shown to increase an 
individual’s risk for late-onset, sporadic AD. We recently demonstrated 
administration of a TREM2-agonizing antibody, AL-002a, leads to immune 
modulation, enhanced microglial clustering around amyloid plaques, reduced 
amyloid deposition, and improved cognition in the 5XFAD model of AD. Based on 
these data, we hypothesized that acutely engaging microglia through two receptor 
mechanisms (FcgR and TREM2) would further enhance Ab clearance from the 
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brains of 5XFAD mice. Here we show that dual engagement of these microglial 
receptors does not further augment Ab clearance, but also show that AL-002a 
appears to have similar efficacy as the well-characterized N-terminal anti-Ab 
antibody. We also found some unique patterns of Ab reductions, notably, only anti-
Ab alone increased insoluble Ab40, the Ab species associated with cerebral 
amyloid angiopathy. Collectively, the data indicate that AL-002a is as efficacious 
as anti-Ab and may not induce the vascular accumulation of amyloid that has been 
observed following treatment with some anti-Ab antibodies.  
 
Introduction 
Alzheimer’s disease (AD) is the most common form of dementia and is 
characterized pathologically by amyloid plaques consisting of aggregated Ab 
peptide, neurofibrillary tangles comprised of hyperphosphorylated tau protein, and 
evident neuronal loss [3, 8, 9]. To date, the main theoretical construct underlying 
AD progression is the amyloid cascade hypothesis. This hypothesis posits that 
neurofibrillary tangle formation, neurodegeneration, and dementia are the 
downstream consequences of Ab deposition and toxicity [12, 13]. Overwhelming 
support for the amyloid cascade hypothesis has encouraged therapeutic targeting 
of Ab, resulting in both active and passive Ab immunization strategies. Active 
immunization strategies consist of vaccination with the full-length Ab1-42 peptide to 
induce the formation of anti-Ab antibodies, whereas passive immunization 
strategies utilize monoclonal antibodies against Ab. Both strategies have 
demonstrated efficacy in clearing Ab from the brain and improving cognition in 
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transgenic models of AD [98, 106, 107, 109, 117, 119]. Proposed mechanisms of 
action of anti-Ab antibodies include the sequestration of circulating Ab resulting in 
an increased net efflux of Ab from the brain into the plasma [119], disaggregation 
and solubilization of Ab [120], and microglial recruitment followed by Fcg receptor 
(FcgR)-mediated phagocytosis [105, 117].  
As the brain’s resident macrophages, microglia possess a wide variety of 
receptors that allow them to identify and internalize pathogens. Under 
physiological conditions, microglia exhibit a ramified morphology and actively 
survey their environment for pathological substrates. Conversely, in the presence 
of a pathological substrate, microglia transform into fully immunocompetent cells 
and become activated. In the midst of this transition, microglia acquire proliferative, 
secretory, phagocytic, and antigen-presenting cell properties. These functional 
changes are accompanied by morphological changes during which microglia 
retract their ramifications and acquire a round, amoeboid shape. Activated 
microglia are ultimately recruited by chemotactic signals to the affected region 
where they phagocytose the identified pathogen. The enhanced phagocytic 
capacity exhibited by activated microglia is due largely in part to their upregulation 
of the following surface receptors: CR3, MHC I, MHC II, CD45, CD68, and FcgR1 
[210].  
Fcg receptors (FcgRs) bind the constant domain (Fc) of immunoglobins (Ig) 
and are among the best characterized phagocytic receptors. The FcgR1 is 
comprised of three chains: the a chain, which is important for ligand recognition, 
and the b and g chains which are necessary for intracellular signaling. Binding of 
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the FcgR1 to an opsonized antigen activates the FcgR1. Activation of the FcgR1 
results in phosphorylation of tyrosine residues on the immunoreceptor tyrosine-
based activation motif (ITAM) region of the g chain by SRC kinase [211]. 
Phosphorylation of the g chain induces the recruitment of spleen tyrosine kinase 
(SYK), and subsequent activation of PLCg and DAG, thereby enhancing 
phagocytosis [211] (Figure 3.1). Activation of microglia has been shown to occur 
with the evolution of amyloid plaques from diffuse to compact [212] and numerous 
studies have demonstrated the ability of microglia to phagocytose Ab1-42 [53, 213-
215]. The role of FcgRs in microglia of healthy and AD brains was first suggested 
by Peress et al. [216] and microglia are now hypothesized to eliminate amyloid 
deposits by coating them with opsonins (anti-Ab antibodies) and phagocytosing 
the opsonized Ab via FcgRs. This hypothesis is supported by data from an ex vivo 
assay demonstrating that anti-Ab F(ab’)2 fragments, which lack the Fc domain, fail 
to activate microglia and are less efficient in reducing fibrillar amyloid [106].    
Recently, the importance of another microglial cell surface receptor has 
been revealed. Triggering receptor expressed on myeloid cells-2 (TREM2) is a 
transmembrane protein expressed exclusively in the brain by microglia [124-132]. 
Importantly, TREM2 binds a variety of ligands including Ab. Because TREM2 has 
a short cytoplasmic tail, it requires aid from its associated intracellular adaptor 
protein (DAP12) to mediate its signaling functions, however, downstream of 
DAP12, TREM2 shares the same intracellular signaling pathway to promote 
phagocytosis. As shown in Figure 3.1, ligand binding to TREM2 results in the 
phosphorylation of tyrosine residues on the ITAM region of DAP12 by SRC and 
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subsequent recruitment of SYK. SYK activation, in turn, activates PLCg and DAG, 
thereby enhancing phagocytosis. In 2013, two genome-wide association studies 
(GWAS) found that heterozygous expression of the TREM2 variants R47H and 
D87N was significantly associated with increased risk for late-onset AD [154, 155]. 
Numerous studies have since replicated the association of these TREM2 variants 
with AD, demonstrating that these variants impair TREM2 signaling [138, 166], 
influence ligand binding affinity [135, 137, 141], and diminish phagocytic capacity 
[137, 167]. To date, several laboratories have assessed whether partial or 
complete loss of TREM2 function contributes to Ab deposition or Ab-associated 
microglial activation and phagocytosis. Notably, studies have consistently shown 
that TREM2 deficiency results in a strong reduction in Ab-associated microgliosis, 
further supporting the notion that the loss of TREM2 function is detrimental in the 
AD brain. Our lab recently demonstrated administration of a TREM2 agonizing 
antibody, AL-002a, modulated the immune response, enhanced microglial 
clustering around amyloid plaques, reduced amyloid deposition, and improved 
cognition in the 5XFAD model of AD.  
In the current study, we tested the hypothesis that acutely engaging 
microglia through both the TREM2 and Fcg receptor mechanisms would act in an 
additive way to enhance Ab clearance from the brains of transgenic mice. To test 
this hypothesis, we used 5XFAD mice, which express five familial-AD-associated 
mutations (3 APP mutations and 2 PS1 mutations) and rapidly develop severe 
amyloid pathology [61]. Using this model, we administered one of six antibody sets: 
AL-002a, anti-Ab, a combination of the two, or one of three isotype-matched 
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experimental controls. We found that dual engagement of these microglial 
receptors does not further augment Ab clearance, but AL-002a appears to have 
similar efficacy as the well-characterized N-terminal anti-Ab antibody.  
 
Materials and Methods 
Study Design: This study was designed to test the hypothesis that acutely 
engaging microglia through two receptor mechanisms (FcgR and TREM2) will 
enhance amyloid clearance in the 5XFAD transgenic mouse model of AD. Sample 
size for the studies performed was calculated based on the sample size required 
to see a 30% reduction in brain Ab levels.  Our endpoints were determined ahead 
of the initiation of study and were based on disease-relevant outcomes 
hypothesized to be affected by TREM2 and FcgR agonism. Mice were randomized 
into groups using a random number generator. All studies were blinded. Antibodies 
were received numbered 1-6 with no other identifying information. Unblinding 
occurred only after all primary endpoint data were collected. We selected the 72-
hour time-point to harvest tissue based on a published time-course of acute anti-
Ab antibody injection that revealed the optimal timepoint to examine the brain post-
injection is 72 hours [105]. More specifically, this study found that by 4 hours post-
injection there is broad distribution of the antibody and by 24 hours there is a 
reduction in diffuse Ab deposits near both injection sites. However, this reduction 
in diffuse amyloid was shown to occur in the absence of significant microglial 
activation as assessed by the known microglial activation markers CD45 and MHC 
ll. Conversely, by 72 hours post-injection parallel reductions in compact, fibrillar 
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amyloid deposits and increased microglial activation were observed, supporting a 
causal role for microglial activation in the clearance of compact amyloid.  
 
Animals. 5XFAD transgenic mice overexpressing the K670N/M671L (Swedish), 
I716V (Florida), and V717I (London) mutations in human APP (695), as well as the 
M146L and L286V mutations in human PS1 [61] were aged to 3.5 months at 
Taconic and transferred to the University of Kentucky. The study was approved by 
the University of Kentucky Institutional Animal Care and Use Committee and 
conformed to the National Institutes of Health Guide for the Care and Use of 
Animals in Research. All studies were performed blinded. Alector provided the 
antibodies coded 1-6 and the mice were also coded and randomized to one of six 
groups. Only upon completion of the data analysis were the groups unblinded. 
Only male mice were used in the current study as the 5XFAD mice have been 
shown to have sex-dependent differences in amyloid deposition [61, 217]. 
Additionally, it is worth noting that wildtype (WT) littermates were included to check 
for an abnormal, off target, inflammatory response following treatment with an 
assigned antibody. Having confirmed there were no inappropriate immune 
responses in WT mice, we focused on the comparisons of the different antibody 
groups within the 5XFAD genotype.  
 
Intracranial Administration: Five-month old male 5XFAD mice and male wildtype 
littermates were assigned to one of six injection groups: AL-002a (IgG1 isotype; 
Alector) N= 14 5XFAD, N= 6 WT; IgG1 (mouse IgG1 kappa monoclonal; MOPC; 
 70 
control antibody for AL-002a; Alector) N= 14 5XFAD, N= 5 WT; anti-Ab (IgG2a 
isotype; Alector) N= 14 5XFAD, N= 7 WT; IgG2a (mouse IgG2a kappa monoclonal; 
MOPC; control antibody for anti-Ab; Alector) N= 13 5XFAD, N= 7 WT; AL-002a + 
anti-Ab (Alector) N= 13 5XFAD, N= 5 WT; IgG1 + IgG2a (Alector) N= 13 5XFAD, 
N= 6 WT. The uneven group numbers reflect the death of some animals during or 
immediately following stereotactic surgery. The n numbers provided reflect only 
those animals that completed the study. Animals that died prior to the completion 
of the study were not included in post-mortem statistical analyses. Notably, deaths 
appeared to be unrelated to treatment with any specific antibody. It is worth noting 
that the anti-Ab antibody used here is most similar to Aducanumab, an IgG2a 
isotype that has been shown to selectively bind insoluble fibrillar and soluble 
oligomeric Ab aggregates at the extreme amino terminus (Ab3-7) [218]. On the day 
of surgery mice were weighed, anesthetized with isoflurane, and placed in a 
stereotaxic apparatus (51733D digital dual manipulator mouse stereotaxic frame; 
Stoelting). A mid-sagittal incision was made to expose the cranium and four burr 
holes were drilled with a dental drill mounted in the stereotaxic frame over the 
frontal cortex and hippocampus to the following coordinates: frontal cortex, 
anteroposterior, +2.0 mm, lateral ± 2.0 mm; hippocampus, anteroposterior -2.7 
mm; lateral ± 2.5 mm, all taken from bregma. A 26-guage needle attached to a 10 
mL Hamilton syringe containing the solution to be injected was lowered 3.0 mm 
ventral to bregma, and a 2 µL injection was made over a 2-minute period. The AL-
002a and IgG2a antibodies were diluted to a final concentration of 5 mg/kg in 1X 
PBS. The anti-Ab and IgG1 antibodies were diluted to a final concentration of 2 
 71 
mg/kg in 1X PBS. The incision was cleaned and closed with surgical staples. 
Buprenophine hydrochloride diluted to 0.015 mg/mL was intraperitoneally injected 
immediately post-surgery at 0.1 mg/kg dose per body weight. Animals received 
subsequent doses every 12 hours until sacrifice. Tissue was harvested 72 hours 
post injection.  
 
Tissue Processing: Mice were perfused intracardially with 25mL of normal saline. 
Brains were rapidly removed and bisected in the mid-sagittal plane. The left half 
was immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours. The 
right half was dissected into cerebral cortex (anterior and posterior), hippocampus, 
striatum, thalamus, and cerebellum. The dissected pieces were flash frozen in 
liquid nitrogen and stored at -80°C. The left hemibrain was passed through a series 
of 10, 20, and 30% sucrose solutions as cryoprotection, 24 hours each, and 25µm 
frozen horizontal sections were collected using a sliding microtome and stored 
floating in PBS containing sodium azide at 4°C. Sections were collected 
sequentially.   
 
Histology and Immunohistochemistry: Six sections spaced 300µm spanning the 
estimated injection site were mounted and stained by mouse IgG to identify the 
injection site. For all subsequent histology and immunohistochemistry, six sections 
spanning the injection site, spaced ~100 µm apart, were selected and analyzed. 
Sections were mounted onto slides and stained for Congo red as previously 
described [109, 219]. Free-floating immunohistochemistry for Ab (4G8; biotinylated 
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mouse monoclonal Ab17-24; Biolegend, San Diego, CA, USA ) was performed. 
Briefly, sections were quenched for endogenous peroxidase, blocked and 
permeabilized. They were then incubated overnight in primary antibody at 4°C 
(1:3000). Sections were then washed and incubated for 1 hour in ABC. DAB was 
used for color development. Stained sections were mounted, air dried overnight, 
dehydrated, and coverslipped in DPX (Electron Microscopy Sciences, Hatfield, PA, 
USA). Immunohistochemical analysis was performed by measuring the percent 
area occupied by positive immunostain using the Nikon Elements BR image 
analysis system (Melville, NY, USA) as previously described.  
 
Ab Multiplex ELISA: Biochemical analysis of Ab levels was performed using the 
commercially available V-PLEX Ab Peptide Panel 1 (6E10) Kit (MSD, Rockville, 
MD, USA). Briefly, soluble protein was extracted from the right frontal cortex using 
MPER lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with complete 
protease and phosphatase inhibitor (Pierce Biotechnology, Waltham, MA, USA). 
Following centrifugation, the resulting supernatant and pellet were separated. The 
supernatant was labeled the “soluble” extract, whereas the pellet was 
homogenized in 70% formic acid. The homogenized pellet was then subject to 
centrifugation and neutralization with 1M Tris-HCL and ultimately labeled the 
“insoluble” extract. Protein concentrations were determined using the BCA protein 
assay kit (Pierce Biotechnology, Waltham, MA, USA). The Meso-Scale Discovery 
(MSD) multiplex ELISA system was then used to measure Ab1-38, Ab1-40, and Ab1-
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42 levels in both the soluble and insoluble extracts. It may be noted that in both the 
soluble and insoluble extracts Ab1-38 levels were below the detectable range.  
 
Inflammation Multiplex ELISA: Biochemical analysis of 10 proinflammatory 
cytokines (IFN-g, TNFa, KC/GRO, IL1-b, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12p70) 
was performed using the commercially available V-PLEX Proinflammatory Panel 
1 Mouse Kit (MSD, Rockville, MD, USA). Soluble protein was extracted from the 
right frontal cortex using MPER lysis buffer (Thermo Fisher Scientific, Waltham, 
MA, USA) with complete protease and phosphatase inhibitor (Pierce 
Biotechnology, Waltham, MA, USA). Protein concentrations were determined 
using the BCA protein assay kit (Pierce Biotechnology, Waltham, MA, USA). The 
Meso-Scale Discovery (MSD) multiplex system was then used to measure levels 
of the aforementioned cytokines.  
 
Analysis: Data are presented as mean ± SEM. Statistical analysis was performed 
using JMP statistical analysis program (SAS Institute). Outlying data points were 
identified using Grubb’s Test. As a result, two data points were excluded from the 
4G8 immunostain statistical analysis. No other data points were excluded. One-
way ANOVA and two-way factorial ANOVA were used, where appropriate, to 
detect treatment differences and differences within treatment groups. Student’s t 
Test was used for post-hoc comparisons. Statistical significance was assigned 
where the p value was lower than 0.05. 
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Results 
Total Ab immunohistochemistry was used to determine the efficacy of co-
administration of AL-002a and anti-Ab in reducing Ab levels. In the current study 
we performed immunohistochemistry for total Ab using the 4G8 antibody, which 
binds the middle portion of the Ab peptide (amino acids 17-24). Considering the 
anti-Ab antibody being injected binds the N terminus (1-16) of the Ab peptide, 4G8 
will avoid reduced staining due to antigen masking. Immunohistochemistry for total 
Ab, which detects both diffuse and compact amyloid, in 5XFAD mice receiving a 
control antibody (IgG1, IgG2a, or a combination of the two) demonstrate a staining 
pattern consistent with those reported by ourselves and others [61]. 5XFAD mice 
receiving a combination of AL-002a and anti-Ab show non-significant, but trending, 
reductions in Ab immunohistochemistry in the frontal cortex and hippocampus 
compared to those receiving a combination of IgG1 and IgG2a control antibodies 
(Figure 3.2). Notably, reductions in Ab in 5XFAD mice receiving the combination 
therapy (AL-002a and anti-Ab) were no greater than those receiving only AL-002a 
or anti-Ab (Figure 3.2).  
Biochemical quantification of the soluble and insoluble Ab species Ab1-38, 
Ab1-40, and Ab1-42 extracted from the right frontal cortex was also performed. It may 
be noted that in both the soluble and insoluble extracts, Ab1-38 levels were below 
the detectable range, which is typical of the 5XFAD mice and is the result of the 
PS1 mutations driving cleavage at the Ab1-42 peptide length, and less so at the Ab1-
38 and Ab1-40 lengths [220]. No significant differences in soluble Ab species were 
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observed in any of the groups, likely due to considerable variation among the 
individual samples (Figure 3.4). Interestingly, intracranial administration of anti-Ab 
significantly increased the concentration of insoluble Ab1-40 and decreased that of 
Ab1-42 compared to administration of the relevant isotype control (IgG2a) (Figure 
3.3). Concentrations of insoluble Ab species were not significantly affected by co-
administration of AL-002a and anti-Ab, or AL-002a alone (Figure 3.3).  
As discussed, there is a large body of evidence supporting a causal role for 
microglial activation in the clearance of amyloid, especially compact amyloid. 
Moreover, one of the proposed mechanisms for anti-Ab immunotherapy’s 
reduction of Ab involves activation of microglia leading to phagocytosis (Figure 
3.1). However, in addition to triggering phagocytosis, activation of microglia results 
in their production of proinflammatory cytokines, which have been implicated in 
both neurodegeneration and neuroprotection. Here we used a sensitive sandwich 
ELISA platform to characterize the expression of well-known proinflammatory 
proteins in the right frontal cortex of treated 5XFAD mice (Figures 3.5 & 3.6). We 
found that intracranial co-administration of AL-002a and anti-Ab only significantly 
increases the expression of KC/GRO, also known as CXCL1 (Figure 3.5). 
Conversely, treatment with AL-002a increases the expression of both TNFa and 
IL-1b (Figure 3.5).    
 
Discussion 
Recent GWAS studies have suggested the risk for sporadic AD is driven by 
a number of distinct pathways including neuroinflammation, a response regulated 
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primarily by microglia and astrocytes. Microglial activation is characterized by 
changes in microglial morphology and function. Morphologically, activation of 
microglia involves a transition from their characteristic, homeostatic ramified 
morphology to an amoeboid pathology. Activated microglia also acquire 
proliferative, secretory, phagocytic, and antigen-presenting cell properties and are 
ultimately recruited by chemotactic signals to sites of pathology where they 
phagocytose the identified pathogen. Therapeutic approaches to the treatment of 
AD continue to focus on one of the major pathological hallmarks of AD, amyloid 
plaques, and in doing so take advantage of microglial activation. Both active and 
passive Ab immunization strategies have demonstrated efficacy in reducing brain 
Ab load and improving cognition in animal models of AD [98, 101, 102, 105, 107, 
117, 119]. One proposed mechanism of action of anti-Ab antibodies is microglial 
Fcg receptor-mediated phagocytosis [107, 117]. Surface expression of FcgR is 
upregulated when microglia become activated and activation of this receptor 
induces phagocytosis through downstream activation of PLCg (Figure 3.1).  
Recently, loss of function mutations in another microglia surface 
immunoreceptor, TREM2, have been shown to increase an individual’s risk for 
late-onset AD [154, 155]. This enhanced risk is believed to arise in part from 
reduced phagocytic capacity of a non-functional TREM2 receptor. Similar to the 
signaling cascade observed with FcgR-mediated phagocytosis, binding of a ligand 
to TREM2 normally induces phagocytosis through downstream activation of PLCg 
(Figure 3.1). Our lab has previously shown a TREM2 agonizing antibody 
developed by Alector, AL-002a, activates TREM2 signaling in vitro and in vivo 
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whether injected intracranially or intraperitoneally. We also demonstrated the 
efficacy of AL-002a in activating microglia, enhancing the number of microglia 
clustered around plaques, reducing amyloid deposition, and improving cognition in 
the 5XFAD model of AD. These results are discussed in depth in chapter 1. 
Because anti-Ab and TREM2 immunotherapy induce phagocytosis via FcgR-
mediated and TREM2-mediated phagocytosis, respectively, our hypothesis in the 
current study was that dual engagement of microglia through each of these 
receptor mechanisms would additively augment amyloid clearance in the 5XFAD 
model of AD.  
Ultimately, the anti-Ab and AL-002a antibodies developed by Alector were 
shown to reduce amyloid deposition, though dual engagement of microglial 
phagocytosis was no more efficacious than engagement of FcgR or TREM2 alone 
(Figures 3.2 & 3.3). 5-month-old 5XFAD mice display significant amyloid pathology 
in the frontal cortex and hippocampus [61]. Receptor saturation refers to the state 
in which all receptors are effectively occupied at a given time. It is possible that the 
abundance of Ab in the brains of 5XFAD mice leads to saturation of both the FcgR 
and TREM2 surface immune receptors. Thus, we hypothesize the lack of additive 
amyloid clearance is due to the fact that individual microglia can only be stimulated 
to phagocytose so much of a given pathogen. The significantly increased insoluble 
Ab1-40 is notable because this species is associated with cerebral amyloid 
angiopathy (CAA) in humans, and CAA has been shown to be increased with anti-
Ab antibody treatment [221].  
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Acute co-administration of anti-Ab and AL-002a does not appear to induce 
significant production of neurotoxic, proinflammatory cytokines (Figures 3.5 & 3.6). 
Rather, co-administering anti-Ab and TREM2 only upregulates the expression of 
KC/GRO, otherwise known as CXCL1, when compared to treatment with anti-
Ab alone (Figure 3.5). The upregulation of CXCL1 as a result of acute combination 
therapy is interesting. CXCL1 has been shown to be expressed by macrophages 
and act as a chemoattractant for leukocyte recruitment [222]. This is interesting 
given that ample literature supports the notion that two different types of microglia 
exist in the brain, resident microglia and those derived from bone-marrow-derived 
(BMD) macrophages [223-227]. Studies also suggest that a limited number of BMD 
macrophages are recruited into the normal adult brain after which they differentiate 
into functional parenchymal microglia. Moreover, data from transgenic models 
suggest that BMD macrophages are consistently recruited to sites of amyloid 
pathology [228-231]. Importantly, BMD macrophages have been shown to exhibit 
higher levels of proteins necessary for antigen presentation and are therefore 
hypothesized to be more efficient at preventing the formation of or eliminating Ab 
[232-234]. In 2013, Zhang et al. assessed transcriptional differences between BMD 
macrophages of AD patients and aged-matched controls to identify the 
determinants allowing transmigration of these cells across the blood-brain-barrier 
(BBB) [235]. This study found that BMD macrophages from AD patients 
overexpress CXCL1, which interacts with CXC chemokine receptor 2 (CXCR2) to 
facilitate transendothelial migration through endothelial tight junctions [235]. 
Another study found that expression of CXCR2, the only receptor identified for 
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CXCL1, is strongly upregulated in neuritic plaques [236]. Collectively, these data 
suggest that acute co-administration of anti-Ab and AL-002a may encourage 
infiltration of bone marrow-derived macrophages from the blood into the brain 
parenchyma. Additionally, we found that acute administration of AL-002a, but not 
anti-Ab, increases levels of the pro-inflammatory cytokines TNFa and IL-1b. This 
is interesting given that amyloid modifying therapies such as anti-Ab are known to 
induce the expression of TNFa and IL-1b. It is likely that modulation of the immune 
response following treatment with AL-002a operates on a different time course and 
that by 72 hours post-injection, anti-Ab has already induced and resolved 
increased levels of TNFa and IL-1b. However, we cannot be certain of this 
explanation given that the aforementioned published time-course of acute anti-Ab 
antibody injection did not address the expression of specific cytokines.  
Numerous studies indicate microglial phagocytosis is defective in the AD 
brain. Our data ultimately supports the microglial dysfunction hypothesis of AD 
which states that microglia become senescent [237] and that senescence 
profoundly impacts the ability of microglia to phagocytose Ab, further indicating 
phagocytosis is defective as opposed to pathologically activated. Overall, our data 
demonstrate efficacy of both the anti-Ab and AL-002a antibodies in clearing Ab 
from the brains of 5XFAD mice and reveal that this clearance may in part be due 
to the infiltration of peripheral monocytes. Subsequent studies comparing the 
actions of these antibodies when administered chronically will be discussed in 
chapter 4.  
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Figure 3.1: Engagement of both the microglial Fcg and TREM2 surface 
immunoreceptors induces receptor-mediated phagocytosis. Binding of the a 
chain of the FcgR to opsonized Ab (Ab coated with anti-Ab antibodies and therefore 
tagged for destruction) results in phosphorylation of the ITAM region of the FcgR g 
chain by SRC kinase. This phosphorylation subsequently recruits SYK, whose 
activation induces the activation of PLCg, DAG, and IP3, thereby promoting 
phagocytosis. Similarly, binding of the Ab peptide to the TREM2 receptor results 
in phosphorylation of the ITAM region of its associated intracellular adaptor protein, 
DAP12, by SRC. This phosphorylation also induces the recruitment of SYK and 
subsequent activation of PLCg, DAG, and IP3, resulting in phagocytosis.  
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Figure 3.2: Intracranial co-administration of TREM2 agonizing and anti-
Ab antibodies does not lead to additive reductions in Ab load. Representative 
images of Ab staining in the hippocampus of 5XFAD mice injected with IgG1 (A), 
with IgG2a (B), with both IgG1 and IgG2a antibodies (C), AL-002a (D), with anti-
Ab (E), and with both AL-002a and anti-Ab antibodies (F) are shown. Scale Bar: 
(A) 100 µM. Quantification of percentage positive immunostain in the frontal cortex 
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(G) and hippocampus (H). *p<0.05, **p<0.01, compared with 5XFAD injected with 
the relevant control antibody. It is worth noting that, with respect to the 
hippocampus, the p value for 5XFAD mice injected with both AL-002a and anti-
Ab compared to those injected with both IgG1 and IgG2a was 0.0508.  
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Figure 3.3: Biochemical quantification reveals intracranial co-administration 
of AL-002a and anti-Ab does not additively reduce insoluble Ab1-40 or Ab1-42. 
Data are represented as mean ± SEM. *p<0.05, **p<0.01, compared with 5XFAD 
injected with the relevant control antibody. #p<0.05, compared with 5XFAD 
injected with a different experimental antibody. It is worth noting that, with respect 
to insoluble Ab1-42, the p value for 5XFAD mice injected with both AL-002a and 
anti-Ab compared to those injected with both IgG1 and IgG2a was 0.0506.  
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Figure 3.4: Biochemical quantification reveals intracranial co-administration 
of AL-002a and anti-Ab does not additively reduce soluble Ab1-40 or Ab1-42. 
Data are represented as mean ± SEM. *p<0.05, **p<0.01, compared with 5XFAD 
injected with the relevant control antibody.  
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Figure 3.5: Pro-inflammatory cytokines whose expression were significantly 
influenced by antibody treatment. Data are represented as mean ± SEM. 
*p<0.05, **p<0.01, compared with 5XFAD injected with the relevant control 
antibody. #p<0.05, ##p<0.01, compared with 5XFAD injected with a different 
experimental antibody.  
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Figure 3.6: Pro-inflammatory cytokines whose expression was not 
significantly influenced by antibody treatment. Data are represented as mean 
± SEM. 
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Chapter 4 
 
Agonism of TREM2 by an activating antibody ameliorates cerebrovascular 
adverse events normally associated with anti-Ab immunotherapy. 
 
Abstract: 
Despite significant mouse model data demonstrating both pathological and 
cognitive efficacy of anti-Ab immunotherapy, clinical trials continue to fail to meet 
primary endpoints for efficacy. Dosage for anti-Ab immunotherapy is limited in 
order to minimize the occurrence of cerebrovascular adverse events, namely 
microhemorrhages and vasogenic edema. As a result of the Ab-targeted 
immunotherapy failures, identifying alternate therapeutic strategies is of 
paramount importance, and targeting neuroinflammation through TREM2 is such 
an approach. Though our previous work demonstrated acute administration of a 
combination of TREM2-agonizing (AL-002a) and anti-Ab antibodies did not 
additively reduce Ab deposition, it suggested that AL-002a has similar efficacy to 
a well characterized anti-Ab antibody in reducing Ab deposition in the brains of 
5XFAD mice. Chronic, systemic administration is more clinically relevant, and so 
we tested the hypothesis that systemic co-administration of AL-002a, a TREM2 
agonizing antibody, and an N-terminal anti-Ab antibody, would additively augment 
Ab clearance from the brains of 5XFAD mice. Though we demonstrate that 
systemic co-administration does not additively reduce Ab deposition, we show that 
AL-002a is as efficacious as an anti-Ab antibody in preventing the deposition of 
newly-generated Ab when administered systemically. Notably, the reduction in Ab 
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following treatment with the anti-Ab antibody was associated with an increase in 
the incidence of microhemorrhage whereas reduction of Ab by AL-002a was 
significant in the absence of cerebrovascular pathology. Moreover, combined 
treatment using AL-002a and an anti-Ab antibody also showed reduced 
Ab deposition in the absence of cerebrovascular adverse events. Our data 
therefore ultimately demonstrate that agonization of TREM2 may be a promising 
new immunotherapy for the treatment of late-onset AD.  
 
Introduction: 
Alzheimer’s disease (AD) is the most common form of dementia and is 
characterized by three pathological hallmarks: 1) extracellular amyloid plaques 
consisting of aggregated Ab peptide, 2) neurofibrillary tangles comprised of 
hyperphosphorylated tau protein, and 3) neuronal loss [3, 8, 9]. The main 
theoretical construct underlying AD progression is the amyloid cascade 
hypothesis, which posits that neurofibrillary tangle formation, neurodegeneration, 
and dementia are downstream consequences of Ab deposition and toxicity [12, 
13]. Overwhelming support for the amyloid cascade hypothesis continues to 
encourage therapeutic targeting of the Ab peptide. One of the most extensively 
characterized therapeutics for AD is anti-Ab immunotherapy, which uses 
antibodies against Ab to promote its clearance from the brain via microglial Fcg-
receptor (FcgR)-mediated phagocytosis [105, 117]. Despite significant mouse 
model data demonstrating pathological and cognitive efficacy of anti-Ab 
immunotherapy, virtually all clinical trials of Alzheimer’s drugs fail. Furthermore, 
 89 
MRI signal alterations, thought to represent vasogenic edema and cerebral 
microhemorrhages, have been associated with a number of Ab-targeted 
immunotherapies, thereby necessitating the need for novel AD therapeutic targets 
[114, 116]. 
Recent GWAS studies have identified the importance of the microglial 
surface immunoreceptor TREM2 [154, 155], which appears to be the most 
significant immune-associated gene influencing AD risk. To date, several 
laboratories have assessed whether partial or complete loss of TREM2 function 
contributes to Ab deposition. Their efforts have consistently shown that TREM2 
deficiency results in a strong reduction in Ab-associated microgliosis, ultimately 
supporting the notion that loss of function of TREM2 is detrimental to the AD brain. 
Previous work from our lab has shown that administration of a TREM2 agonizing 
antibody, AL-002a, modulated the immune response, enhanced microglial 
clustering around amyloid plaques, reduced amyloid deposition, and improved 
cognition in the 5XFAD model of AD.  
Recently, our lab has shown that acute engagement of both the Fcg and 
TREM2 microglial receptors through anti-Ab and TREM2-agonizing antibodies 
does not further augment Ab clearance. However, we also demonstrated that the 
TREM2 agonizing antibody AL-002a appears to have similar efficacy in the 
reduction of Ab deposition as the well-characterized anti-N-terminal Ab antibody. 
Considering replication of these data in a systemic study could have significant 
clinical implications moving forward, we tested the hypothesis that systemic co-
administration of AL-002a and an anti-Ab antibody would additively augment Ab 
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clearance from the brains of 5XFAD mice. Notably, previous work from our lab also 
demonstrated that the anti-Ab antibody, but not AL-002a, increases levels of 
insoluble Ab1-40, the Ab species associated with cerebral amyloid angiopathy [238, 
239], in turn suggesting that AL-002a does not induce the vascular accumulation 
of amyloid commonly observed with Ab immunotherapy. Based on these data, we 
also hypothesized that agonism of TREM2 would reduce the incidence of 
cerebrovascular adverse events typically associated with anti-Ab immunotherapy.  
To test these hypotheses, we used 5XFAD mice, which express five 
familial-AD-associated mutations (3 APP mutations and 2 PS1 mutations) and 
rapidly develop severe amyloid pathology [61]. Using this model, we administered 
one of six antibody sets: AL002a, anti-Ab, a combination of the two, or one of three 
isotype-matched experimental controls. Similar to our results from the acute study, 
we found that chronic engagement of the Fcg and TREM2 microglial receptors 
does not further augment Ab clearance. Importantly, biochemical quantification of 
soluble and insoluble Ab species indicate that AL-002a is as efficacious in 
preventing additional Ab deposition as a well-characterized N-terminal anti-Ab 
antibody. Notably, treatment with the anti-Ab antibody was shown to significantly 
increase the incidence of microhemorrhage whereas reduction of Ab by AL-002a 
was shown to occur in the absence of cerebrovascular pathology.  
 
Material and Methods: 
Study Design: This study was designed to test two hypotheses: 1) that systemic 
co-administration of AL-002a and an anti-Ab antibody will further enhance amyloid 
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clearance in the 5XFAD transgenic mouse model of AD, and 2) that agonism of 
TREM2 via AL-002a will reduce the incidence of cerebrovascular adverse events 
typically associated with anti-Ab immunotherapy. Sample size for the studies 
performed was determined by statistical power analyses with behavior as the 
primary outcome for power calculations due to it being the most variable outcome. 
Our endpoints were determined ahead of the initiation of study and were based on 
disease-relevant outcomes hypothesized to be affected by TREM2 and FcgR 
agonism. Mice were randomized into groups using a random number generator. 
All studies were blinded. Antibodies were received numbered 1-6 with no other 
identifying information. Unblinding occurred only after all primary endpoint data 
were collected.  
 
Animals. 5XFAD transgenic mice overexpressing the K670N/M671L (Swedish), 
I716V (Florida), and V717I (London) mutations in human APP (695), as well as the 
M146L and L286V mutations in human PS1 [61] were aged to 3.5 months at 
Taconic and transferred to the University of Kentucky. The study was approved by 
the University of Kentucky Institutional Animal Care and Use Committee and 
conformed to the National Institutes of Health Guide for the Care and Use of 
Animals in Research. All studies were performed blinded. Alector provided the 
antibodies coded and the mice were also coded and randomized to one of six 
groups. Only upon completion of the data analysis were the groups unblinded. 
Only male mice were used in the current study as the 5XFAD mice have been 
shown to have sex-dependent differences in amyloid deposition [61, 217].  
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Systemic Administration: Four-month-old male 5XFAD and male wildtype 
littermates were assigned to one of six antibody groups: 1) AL-002a (IgG1 isotype; 
Alector) N=15 5XFAD, N=9 WT; 2) N-terminal anti-Ab (IgG2a isotype; Alector) N= 
17 5XFAD, N= 9 WT; 3) AL-002a + anti-Ab, N =17 5XFAD, N= 12 WT; 4) IgG1 
(mouse IgG1 kappa monoclonal; MOPC; control antibody for AL-002a) N= 15 
5XFAD, N= 10 WT; 5), IgG2a (mouse IgG2a kappa monoclonal; MOPC; control 
antibody for anti-Ab) N= 17 5XFAD, N= 10 WT; or 6) IgG1 + IgG2a, N= 17 5XFAD, 
N= 11 WT. The uneven group numbers reflect the death of some animals 
throughout the course of treatment or following behavior testing. The n numbers 
provided reflect only those animals that completed the study. Animals that died 
prior to the completion of the study were not included in post-mortem statistical 
analyses. Notably, deaths appeared to be unrelated to treatment with any specific 
antibody. It is worth noting that the anti-Ab antibody used here is most similar to 
Aducanumab, an IgG2a isotype that has been shown to selectively bind insoluble 
fibrillar and soluble oligomeric Ab aggregates at the extreme amino terminus (Ab3-
7) [218]. AL-002a and its isotype control were administered at a dose of 
50mg/kg/week. The anti-Ab antibody and its isotype control were administered at 
a dose of 10mg/kg/week. Where mice were receiving combination, they received 
the same dosage of each antibody at the same interval. Mice were subject to 
multiple behavior paradigms during the two weeks prior to sacrifice (i.e. week 12). 
Mice were euthanized and tissue was harvested 24 hours after the final injection.  
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Tissue Processing: Mice were perfused intracardially with 25mL of normal saline. 
Brains were rapidly removed and bisected in the mid-sagittal plane. The left half 
was immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours. The 
right half was dissected into cerebral cortex (anterior and posterior), hippocampus, 
striatum, thalamus, and cerebellum. The dissected pieces were flash frozen in 
liquid nitrogen and stored at -80°C. The left hemibrain was passed through a series 
of 10, 20, and 30% sucrose solutions as cryoprotection, 24 hours each, and 25µm 
frozen horizontal sections were collected using a sliding microtome and stored 
floating in PBS containing sodium azide at 4°C. Sections were collected 
sequentially.   
 
Histology and Immunohistochemistry: Eight serial horizontal sections spaced 1200 
µm apart were selected for free-floating immunohistochemistry for Ab (biotinylated 
mouse monoclonal Ab17-24; Biolegend, San Diego, CA, USA), IBA1 (rabbit 
polyclonal; Wako, Richmond, VA, USA) and CD45 (rat monoclonal; Biolegend, 
San Diego, CA, USA). Briefly, sections were quenched for endogenous 
peroxidase, blocked and permeabilized. They were then incubated overnight in 
primary antibody at 4°C (Ab 1:3000; IBA1 1:1000, CD45 1:3000). After washing, 
sections were incubated for 2 hours in the appropriate biotinylated secondary 
antibody (goat anti-rabbit IgG for IBA1, goat anti-rat IgG for CD45 at 1:3000 and 
1:5000, respectively). Sections were then washed and incubated for 1 hour in ABC. 
DAB with (IBA1, CD45) and without (Ab) nickel was used for color development. 
Stained sections were mounted, air dried overnight, dehydrated, and coverslipped 
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in DPX (Electron Microscopy Sciences, Hatfield, PA, USA). Immunohistochemical 
analysis was performed by measuring the percent area occupied by positive 
immunostain using the Nikon Elements BR image analysis system (Melville, NY, 
USA) as previously described. Additionally, eight serial horizontal sections spaced 
600 µm apart were mounted on sides and stained for Prussian blue as previously 
described [109]. Neutral red was used as a counterstain for Prussian blue.  
 
Ab Multiplex ELISA: Biochemical analysis of Ab levels was performed using the 
commercially available V-PLEX Ab Peptide Panel 1 (6E10) Kit (MSD, Rockville, 
MD, USA). Briefly, soluble protein was extracted from the right frontal cortex using 
MPER lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with complete 
protease and phosphatase inhibitor (Pierce Biotechnology, Waltham, MA, USA). 
Following centrifugation, the resulting supernatant and pellet were separated. The 
supernatant was labeled the “soluble” extract, whereas the pellet was 
homogenized in 70% formic acid. The homogenized pellet was then subject to 
centrifugation and neutralization with 1M Tris-HCL and ultimately labeled the 
“insoluble” extract. Protein concentrations were determined using the BCA protein 
assay kit (Pierce Biotechnology, Waltham, MA, USA). The Meso-Scale Discovery 
(MSD) multiplex ELISA system was then used to measure Ab1-38, Ab1-40, and Ab1-
42 levels in both the soluble and insoluble extracts. It may be noted that in both the 
soluble and insoluble extracts Ab1-38 levels were below the detectable range.  
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Inflammation Multiplex ELISA: Biochemical analysis of 10 proinflammatory 
cytokines (IFN-g, TNFa, KC/GRO, IL1-b, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12p70) 
was performed using the commercially available V-PLEX Proinflammatory Panel 
1 Mouse Kit (MSD, Rockville, MD, USA). Soluble protein was extracted from the 
right frontal cortex using MPER lysis buffer (Thermo Fisher Scientific, Waltham, 
MA, USA) with complete protease and phosphatase inhibitor (Pierce 
Biotechnology, Waltham, MA, USA). Protein concentrations were determined 
using the BCA protein assay kit (Pierce Biotechnology, Waltham, MA, USA). The 
Meso-Scale Discovery (MSD) multiplex system was then used to measure levels 
of the aforementioned cytokines.  
 
MMP ELISA: Biochemical analysis of MMP3 and MMP9 levels was performed 
using the commercially available Mouse Total MMP3 and Mouse Total MMP9 
ELISA Kits (R&D Systems, Minneapolis, MN, USA), respectively. Soluble protein 
was extracted from the right frontal cortex using MPER lysis buffer (Thermo Fisher 
Scientific, Waltham, MA, USA) with complete protease and phosphatase inhibitor 
(Pierce Biotechnology, Waltham, MA, USA). Protein concentrations were 
determined using the BCA protein assay kit (Pierce Biotechnology, Waltham, MA, 
USA). The appropriate ELISA kit was then used to measure levels of MMP3 and 
MMP9.  
 
Radial Arm Water Maze: After 12 weeks of treatment, mice were subject to a two-
day radial arm water maze (RAWM) paradigm, as previously described [68]. On 
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day one, 15 trials were run in two blocks of 6 followed by the last three trials. A 
cohort of 4 mice was run sequentially for each block (i.e. each of 4 mice undergo 
trial one, then the same mice undergo trial two, etc.). After each block, a second 
cohort of mice was run, permitting an extended rest period before mice were 
exposed to the next block of trials. It should be noted that extra wait time was 
added to the end of the block with three trials to ensure the rest period was similar 
throughout testing. The goal arm was different for each mouse in a cohort to 
minimize odor cues. Conversely, the start arm was varied for each trial, with the 
goal arm remaining constant for a given individual for both days. For the first 11 
trials, the platform was alternately visible then hidden (hidden for the last 4 of the 
first 15 trials). On day two, the mice were run in exactly the same manner as day 
one except that the platform remained hidden for all 15 trials. The number of errors 
(incorrect arm entries) were measured in a one-minute time frame. As standard 
practice, mice failing to make an arm choice within 15 seconds were assigned one 
error. In order to minimize the influence of individual trial variability, each mouse’s 
errors for 3 consecutive trials were averaged, producing 5 data points (termed 
“blocks”) for each day. Blocks were then analyzed statistically by repeated 
measures ANOVA using SAS.  
 
Novel Object Recognition: Following the RAWM, the novel object recognition task 
was performed. During the habituation phase, each mouse was gently placed into 
a square box (50 x 50 x 15 cm, length x width x height) for 30 min without any 
objects. During the training phase, two identical objects, A1 and A2, were placed 
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parallel to and near one wall of the square box. Each mouse was placed singly in 
the box and allowed to explore the objects for 5 minutes. Exploratory behavior was 
defined as directing the nose at the object at a distance of less than 2 cm and/or 
touching the object with the nose. The mouse was then returned to its home cage 
with a 1-hour inter-trial interval. Both objects were replaced; one being a familiar 
object (A1) and the other a novel object (B). The mouse was returned to the box 
and allowed to explore the objects for 5 minutes during the test phase. Novel and 
familiar objects were alternated between the left and right positions to reduce 
potential bias toward a particular location. The objects and the box were cleaned 
with 10% ethanol after each individual trial to eliminate olfactory cues. The 
exploration time (s) for each object in the trials was recorded. The preferential 
index (PI) was calculated as [time spent exploring the novel object/total exploration 
time].  
 
Analysis: Data are presented as mean ± SEM. Statistical analysis was performed 
using JMP statistical analysis program (SAS Institute). Outlying data points were 
identified using Grubb’s Test and removed from their respective dataset. RAWM 
data were analyzed by repeated-measures ANOVA. For other data, one-way 
ANOVA and two-way factorial ANOVA were used, where appropriate, to detect 
treatment differences and differences within treatment groups. Student’s t Test 
was used for post-hoc comparisons. Statistical significance was assigned where 
the p value was lower than 0.05. 
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Results: 
Mice were tested in our behavioral paradigms during the two weeks prior to 
sacrifice. The radial arm water maze (RAWM) is a behavioral task that reliably 
detects spatial learning and memory deficits in aged transgenic mice [68]. 5XFAD 
mice were tested after 12 weeks of treatment with either AL-002a, anti-Ab, a 
combination of AL-002a and anti-Ab, or 1 of 3 isotype-matched experimental 
controls. Included in the task were age-matched wildtype littermate mice treated 
with 1 of the 6 aforementioned antibodies. We found that the 5XFAD mice 
receiving IgG1, IgG2a, or a combination of IgG1 and IgG2a were significantly 
impaired compared to 5XFAD mice receiving AL-002a, anti-Ab, or a combination 
of the two (Figure 4.1A). In examining the antibody effects at the end of the second 
day of testing (Block 10), we found a significant reduction in the number of errors 
in the 5XFAD mice receiving AL-002a compared to those receiving the relevant 
control antibody (IgG1) (Figure 4.1B). Importantly, no significant treatment effects 
were observed in wildtype mice, indicating the effects of AL-002a and anti-Ab on 
cognition are genotype specific.  
Within the same week following completion of the RAWM, the Novel Object 
Recognition (NOR) task was performed to investigate short-term recognition 
memory [191]. We found that 5XFAD mice treated with IgG1, IgG2a, or a 
combination of IgG1 and IgG2a spent significantly more time exploring the familiar 
object compared to the 5XFAD mice treated with AL-002a, anti-Ab, or a 
combination of the two (Figure 4.2A). Additionally, the 5XFAD mice treated with 
AL-002a, anti-Ab, or a combination of the two exhibited significantly increased 
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explorative behavior as compared to control antibody treated 5XFAD mice (Figure 
4.2A). Again, no significant treatment effects were observed in wildtype mice, 
indicating the effects of AL-002a and anti-Ab on cognition are genotype specific.  
Total Ab immunohistochemistry was used to determine the efficacy of 
systemic co-administration of AL-002a and anti-Ab in reducing Ab levels. Because 
the anti-Ab antibody being injected binds the N terminus (amino acids 1-16) of the 
Ab peptide, we performed immunohistochemistry for total Ab using the 4G8 
antibody, which binds the middle portion of the Ab peptide (amino acids 17-24). 
4G8 therefore avoids potential reductions in staining due to antigen masking. In 
line with the results of our acute study, here we show that systemic co-
administration of AL-002a and anti-Ab does not additively reduce Ab levels (Figure 
4.3). However, in contrast to the results of our acute study, we also show that 
treatment with AL-002a or anti-Ab alone does not significantly reduce Ab levels in 
the hippocampus, and that only treatment with anti-Ab significantly reduces 
Ab levels in the frontal cortex. It is worth nothing these data regarding Aβ 
reductions following treatment with AL-002a directly contradict previous work 
from our lab (see Chapter 2), and that this discrepancy may be due to the fact that 
these studies used different anti-Ab antibodies for immunohistochemistry.  
Interestingly, co-administration of the two significantly reduces Ab levels in both 
the frontal cortex and hippocampus when compared to 5XFAD mice treated 
with the isotype-matched control. The inconsistencies observed between our 
acute and systemic datasets may be attributable to the fact that while 
antibodies can cross the BBB into the brain parenchyma, they don’t do so very 
well. In fact, only 0.1-0.2% of 
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antibody is able to enter the brain [240]. The disparity in amyloid clearance 
observed in mice treated with AL-002a or anti-Ab may be due to enhanced 
permeability of the BBB following treatment with anti-Ab but not AL-002a. Despite 
these discrepancies, biochemical quantification of several Ab species suggests 
both the AL-002a and anti-Ab antibodies prevent additional deposition of newly-
generated Ab.  
Biochemical quantification of the soluble and insoluble Ab species Ab1-38, 
Ab1-40, and Ab1-42 extracted from the right frontal cortex was also performed. It may 
be noted that in both the soluble and insoluble extracts, Ab1-38 levels were below 
the detectable range, which is typical of the 5XFAD mice and is the result of the 
PS1 mutations driving cleavage at the Ab1-42 length, and less so at the Ab1-40 and 
Ab1-38 lengths [220]. We found that systemic administration of anti-Ab significantly 
decreases levels of insoluble Ab1-40 and Ab1-42, whereas administration of AL-002a 
or a combination of AL-002a and anti-Ab significantly reduces levels of insoluble 
Ab1-42 (Figure 4.4A). Conversely, systemic administration of AL-002a, anti-Ab, or a 
combination of the two significantly increases levels of soluble Ab1-40, whereas only 
the administration of anti-Ab significantly increases levels of soluble Ab1-42 (Figure 
4.4B).  
As previously discussed, one of the proposed mechanisms for anti-Ab 
immunotherapy’s reduction of Ab involves activation of microglia. We therefore 
performed immunohistochemistry for IBA1, which labels both activated and resting 
microglia, to determine whether there was an increase in the total number of 
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microglia. IBA1 staining in the frontal cortex and hippocampus of 5XFAD mice 
revealed that treatment with AL-002a or a combination of AL-002a and anti-
Ab significantly increases the total number of microglia compared to treatment with 
anti-Ab alone (Figure 4.5A).  
Considering activation of microglia is thought to reflect their increased 
expression of proinflammatory cytokines, we used a sensitive sandwich ELISA 
platform to characterize the levels of well-known proinflammatory cytokines in the 
right frontal cortex of treated 5XFAD mice (Figures 4.6 & 4.7). Interestingly, we 
found that treatment with anti-Ab significantly increases the expression of several 
hallmark proinflammatory cytokines, including TNFa, IL-1b, IL-12, IL-6, IL-2, and 
KC/GRO (CXCL1) (Figure 4.6). Conversely, treatment with AL-002a significantly 
increased the expression of the anti-inflammatory cytokine IL-10 (Figure 4.6). It 
may be noted a number of cytokines were unaffected following treatment (Figure 
4.7). 
Given their implication in extracellular matrix degradation, we also used a 
sensitive sandwich ELISA platform to characterize the levels of two matrix 
metalloproteinases (MMPs), MMP3 and MMP9. We found significantly increased 
levels of both MMP3 and MMP9 in 5XFAD mice treated with anti-Ab (Figure 4.8). 
Notably, this effect was not observed among the other treatment groups. 
Moreover, Prussian blue histological analysis revealed a significantly increased 
incidence of microhemorrhage in 5XFAD mice treated with anti-Ab, and this effect 
was not observed among the other treatment groups (Figure 4.9).  
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Discussion: 
Similar to the findings of our acute study, data from this systemic study 
demonstrate that co-administration of AL-002a and anti-Ab followed by 
subsequent dual engagement of the microglial TREM2 and Fcg surface receptors, 
respectively, does not result in additive reductions in Ab deposition. It is intriguing 
that systemic administration of AL-002a, anti-Ab, or a combination of the two 
significantly increased levels of soluble Ab1-40, whereas only treatment with anti-
Ab increased levels of soluble Ab1-42. One of the proposed mechanisms of action 
of anti-Ab immunotherapy is disaggregation and solubilization of Ab. This 
mechanism was first proposed by Solomon et al., who demonstrated that 
antibodies raised against the N-terminal region (amino acids 1-28) of the Ab 
peptide bind Ab, leading to disaggregation and partial restoration of the peptide’s 
solubility [120]. It is possible that treatment with AL-002a, anti-Ab, or a combination 
of the two results in disaggregation of Ab oligomers and the restoration of their 
solubility, which may augment Ab efflux from the brain into the blood via low-
density lipoprotein receptor related protein-1 (LRP1) or through interstitial fluid 
bulk-flow clearance (perivascular drainage) [241-243]. It is worth nothing that 
increased levels of soluble Ab species, concomitant increases in CAA, and an 
increased density of cortical microhemorrhages have been reported in a number 
of human neuropathological studies [42-44]. Interestingly, in one study two of the 
nine patients assessed exhibited almost complete absence of both parenchymal 
amyloid plaques and CAA suggesting that, with time, Ab is eventually cleared from 
the vasculature [44]. Our data are consistent with the hypothesis that Ab 
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immunotherapy results in the solubilization of Ab, but also suggest that only 
treatment with anti-Ab is disaggregating and solubilizing parenchymal amyloid 
plaques.  
By using two distinct behavioral paradigms to test learning and memory in 
the current study, we are confident in concluding that co-administration of AL-002a 
and anti-Ab does not doubly enhance cognition in the 5XFAD model of AD. 
Notably, comparable to data from our acute study, data presented here indicate 
that AL-002a is as efficacious as anti-Ab in the reduction of Ab deposition and that 
the reduction of Ab by AL-002a does not induce cerebrovascular pathology 
observed following treatment with anti-Ab. The absence of cerebrovascular 
pathology following treatment with AL-002a, but not anti-Ab, is likely due to the 
observed differences in immune modulation and matrix metalloprotease (MMP) 
expression.  
It is well understood that microglia express a wide variety of pattern 
recognition receptors (PRRs), which trigger a series of intracellular cascades that 
culminate with the production of pro- and anti-inflammatory cytokines upon 
recognition of a particular pathogen. Thus, depending on the encountered 
pathologic events, microglia are able to exert a variety of effector functions, which 
may be either neurotoxic (pro-inflammatory) or neuroprotective (anti-
inflammatory). It should be noted that the activated microglial response initially 
provides the environment needed for neuronal regeneration and functional 
recovery and is, therefore, neuroprotective. However, dysregulation of the 
microglial inflammatory response may lead to the uncontrolled production of 
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immune mediators as well as the recruitment of peripheral immune cells that 
induce secondary damage to intact tissue [244, 245]. Thus, immune cell activation 
must be tightly regulated in order to avoid bystander degeneration of otherwise 
healthy neurons. Biochemical quantification of a number of cytokines revealed that 
treatment with AL-002a significantly increases levels of the anti-inflammatory 
cytokine IL-10, whereas treatment with anti-Ab significantly increases levels of 
TNFa, IL-1b, IL-12, and IL-6, all of which are considered to be pro-inflammatory.  
The upregulation of IL-10 following treatment with AL-002a, but not anti-Ab, 
is interesting considering the production of IL-10 has been described as one of the 
most important mechanisms evolved by immunologically competent cells to 
counteract damage driven by excessive inflammation [246]. This is because IL-10 
binding to its receptor results in decreased cytokine gene expression as well as 
the downregulation of MHC ll which subsequently decreases antigen presentation 
to T cells [247, 248]. Furthermore, IL-10 has been shown to prevent apoptosis by 
activating the PI3K/AKT signaling cascade, thereby enhancing the expression of 
anti-apoptotic factors [248]. IL-10 has also been shown to inhibit the production of 
pro-inflammatory cytokines by microglia [249, 250] and to act on astrocytes by 
potentiating their production of TGFb [251]. Finally, IL-10 has been shown to 
provide trophic support to neurons and is, therefore, associated with enhanced 
survival [252]. 
In addition to discrepancies in immune modulation, our data demonstrate 
that treatment with anti-Ab, but not AL-002a, induces increased expression of 
MMP3 and MMP9, both of which have been implicated in tight junction breakdown 
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and subsequent blood-brain-barrier (BBB) leakage responsible [253]. MMP9 
belongs to the gelatinase family of MMPs and can therefore degrade gelatin, 
cytokines, and even Ab [254, 255]. Given MMP9’s variety of substrates, its 
expression is tightly regulated by a number of cytokines, growth factors, and other 
proteins. In particular, its expression is induced by the proinflammatory cytokines 
TNFa and IL-1b [256, 257], both of which were upregulated following treatment 
with anti-Ab but not AL-002a. Due to the necessity of its tight regulation, MMP9 is 
secreted as a zymogen that requires cleavage by MMP3, the expression of which 
is also induced by pro-inflammatory cytokines, to become active [258]. Notably, 
MMP9 has been implicated in BBB breakdown following anti-Ab immunotherapy. 
Significant increases in gene expression of MMP3 coupled with significantly 
decreased expression of TIMP1, the endogenous inhibitor of MMP9, were 
observed in AbPPSw/NOS2-/- mice treated with an Ab vaccine [115]. Protein 
measurements confirmed these increased levels and demonstrated that robust 
expression of MMP9 was found to be associated with the vasculature [115]. 
Moreover, similar results have been reported in passively immunized AD 
transgenic mice and are further supported by the data shown here. Interestingly, 
an in vitro study using BV2 cells treated with either an anti-Ab IgG-Ab or anti-tau 
IgG-tau immune complex demonstrated increased MMP3 and MMP9, suggesting 
that activation of MMP9 requires the Fcg receptor [259].  
Collectively, our data suggest AL-002a and anti-Ab function differently to 
reduce Ab deposition in the brains of 5XFAD mice. It is likely that increased levels 
of the proinflammatory cytokines TNFa and IL-1b following treatment with anti-Ab 
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are directly responsible for the observed upregulation of MMP3 and MMP9 and 
subsequent increased incidence of microhemorrhage. Conversely, the absence of 
cerebrovascular pathology in the 5XFAD mice treated with AL-002a is likely due 
to increased levels of IL-10. As discussed previously, IL-10 inhibits the production 
of proinflammatory cytokines, thereby preventing the production of MMP3 and 
MMP9 and, in turn, tight junction breakdown and BBB leakage. Ultimately, our data 
demonstrate that agonism of TREM2 by an activating antibody does not induce 
adverse cerebrovascular events associated with other amyloid-modifying 
therapies, further suggesting that agonization of TREM2 is a promising new 
immunotherapy for the treatment of late-onset AD.  
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Figure 4.1: Systemic administration of AL-002a, anti-Ab, and a combination 
of the two improves spatial learning and memory in 5XFAD mice, but fails to 
significantly effect cognition in wildtype mice. Panel A shows the radial-arm 
water maze data from 5XFAD mice. Blocks 1-5 are day 1, blocks 6-10 are day 2. 
Panel B shows a bar graph to illustrate the difference in the number of errors made 
for the final block of trials (block 10). Panel C shows the radial-arm water maze 
data from wildtype (WT) mice. Panel D shows a bar graph to illustrate the 
difference in the number of errors made for the final block of trials (block 10). Data 
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are represented as mean ± SEM. *p<0.05, **p<0.01, compared with 5XFAD 
injected with the relevant control antibody. 
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Figure 4.2: Systemic administration of AL-002a, anti-Ab, and a combination 
of the two improves recognition memory in 5XFAD mice, but fails to 
significantly effect cognition in wildtype mice. Panel A shows the bar graph for 
the novel object recognition data from 5XFAD mice, where % exploration time with 
the novel object is shown. 50% exploration time would represent chance. Panel B 
shows the bar graph for the novel object recognition data from wildtype mice. Data 
are represented as mean ± SEM. *p<0.05, **p<0.01, compared with 5XFAD 
injected with the relevant control antibody. 
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Figure 4.3: Systemic co-administration of AL-002a and anti-Ab does not lead 
to additive reductions in Ab. Representative images of Ab staining in the 
hippocampus of 5XFAD mice injected with IgG1 (A), with IgG2a (B), with both IgG1 
and IgG2a antibodies (C), AL-002a (D), with anti-Ab (E), and with both AL-002a 
and anti-Ab antibodies (F) are shown. Scale Bar: (A) 100 µM. Quantification of 
percentage positive immunostain in the frontal cortex (G) and (H) hippocampus. 
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*p<0.05, **p<0.01, compared with 5XFAD injected with the relevant control 
antibody. 
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Figure 4.4: Biochemical quantification reveals systemic co-administration of 
AL-002a and anti-Ab does not additively reduce soluble or insoluble Ab 
species. Data are represented as mean ± SEM. *p<0.05, **p<0.01, compared with 
5XFAD injected with the relevant control antibody.  
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Figure 4.5: Systemic administration of AL-002a and a combination of AL-
002a and anti-Ab enhances microglial staining. 
Representative images of IBA-1 staining in the hippocampus of 5XFAD mice 
injected with IgG1 (A), with IgG2a (B), with both IgG1 and IgG2a antibodies (C), 
AL-002a (D), with anti-Ab (E), and with both AL-002a and anti-Ab antibodies (F) 
are shown. Scale Bar: (A) 100 µM. Quantification of percentage positive 
immunostain in the frontal cortex (G) and hippocampus (H).  *p<0.05, **p<0.01, 
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compared with 5XFAD injected with the relevant control antibody. #p<0.05, 
##p<0.01, compared with 5XFAD injected with a different experimental antibody. 
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Figure 4.6: Pro-inflammatory cytokines whose expression were significantly 
influenced by antibody treatment. Data are represented as mean ± SEM. 
*p<0.05, **p<0.01, compared with 5XFAD injected with the relevant control 
antibody. #p<0.05, ##p<0.01, compared with 5XFAD injected with a different 
experimental antibody. It is worth noting that with respect to TNFa, the p value for 
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5XFAD mice treated with anti-Ab compared to those treated with both AL-002a 
and anti-Ab was 0.0533. With respect to KC/GRO, the p value for 5XFAD mice 
treated with AL002a compared to those treated with anti-Ab was 0.0578. 
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Figure 4.7: Pro-inflammatory cytokines whose expression was not 
significantly influenced by antibody treatment. Data are represented as mean 
± SEM. 
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Figure 4.8: Biochemical quantification reveals that treatment with anti-Ab 
increases MMP system markers. Data are represented as mean ± SEM. 
*p<0.05, **p<0.01, compared with 5XFAD injected with the relevant control 
antibody. #p<0.05, ##p<0.01, compared with 5XFAD injected with a different 
experimental antibody. 
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Figure 4.9: Treatment with anti-Ab increases the incidence of Prussian blue 
detected microhemorrhages. Representative images of Prussian Blue staining 
are shown (A & B). Scale Bar: (A) 50 µM. (C) Quantification of the mean number 
of microhemorrhages per section. *p<0.05, **p<0.01, compared with 5XFAD 
injected with the relevant control antibody. #p<0.05, ##p<0.01, compared with 
5XFAD injected with a different experimental antibody. 
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Chapter 5 
 
Discussion 
 
Microglia serve as the resident phagocytes of the brain where they utilize 
their highly motile processes to survey their environment for the presence of 
pathogens such as misfolded or aggregated proteins. In addition to inspecting their 
environment, ramified, or sometimes referred to as “resting,” microglia also provide 
neurotrophic factors that support tissue maintenance and simultaneously 
contribute to the protection and refinement of synapses [260-262]. Upon 
recognition of a pathogen microglia extend their processes to the injury site, later 
migrating to said site and initiating an immune response characterized by the 
secretion of numerous inflammatory mediators. It is, therefore, without question 
that microglia serve a number of crucial roles in the maintenance of brain 
homeostasis. However, in the context of neurodegeneration, inflammation is 
viewed as a double-edged sword given the actions of microglia have been deemed 
both neuroprotective and neurotoxic. Opposing opinions likely arise from the fact 
that acute inflammation protects against invading pathogens and promotes 
healing, whereas chronically sustained inflammation can induce serious damage 
to the host’s own tissue. Opposing views are more likely attributed to the fact that, 
depending on the disease stage and transgenic model, microglia exhibit different 
roles, thereby inducing different effects.   
In the context of Alzheimer’s disease (AD) specifically, numerous studies 
have indicated that microglia recognize and surround amyloid plaques [263-266]. 
Furthermore, inefficient clearance of Ab, one of the three hallmark pathologies of 
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AD, has been identified as a major pathogenic pathway in both early- and late-
onset AD (EOAD and LOAD, respectively) [267, 268]. Studies have shown that Ab 
deposition results in the activation of microglia and the subsequent production of 
cytokines and neurotoxins that, when chronically sustained, induce bystander 
damage to otherwise healthy neurons. Conversely, microglia have also been 
shown to express a variety of surface receptors that promote the clearance and 
phagocytosis of Ab, and thereby restrict senile plaque formation [232, 269-271]. In 
addition to phagocytosing Ab, studies have demonstrated that microglia secrete 
proteolytic enzymes (insulin-degrading enzyme (IDE), neprilysin, matrix 
metalloproteinase 9 (MMP9), and plasminogen) that degrade Ab, which further 
suggests microglia serve neuroprotective roles in the AD brain [255, 272]. Support 
for the hypothesis that compromised microglial function contributes to AD 
pathogenesis comes from rare mutations in TREM2 that confer significantly 
increased risk for LOAD.  
Triggering receptor expressed on myeloid cells-2 (TREM2) is highly 
expressed by microglia and has been shown to mediate phagocytic clearance of 
Ab, amongst other pathogens. In 2013, two genome-wide association studies 
(GWAS) revealed that heterozygous expression of the TREM2 R47H and D87N 
variants were significantly associated with LOAD risk [154, 155]. To date, 
numerous studies have since replicated the association of these and other TREM2 
variants with LOAD [156-161, 163-165]. LOAD-associated variants of TREM2 
have been shown to impair the efficiency of TREM2 signaling, influence ligand 
affinity, and diminish phagocytic capacity. Studies have also assessed whether 
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partial or complete loss of TREM2 function contributes to Ab deposition or Ab -
associated microglial activation and phagocytosis, and consistently show that 
TREM2 deficiency results in a strong reduction in Ab-associated microgliosis. 
Ultimately, human genetics along with biochemical studies assessing the 
functional consequences of TREM2 variants agree that loss of TREM2 function is 
detrimental for the AD brain; Our data supports this conclusion. We have shown 
that agonization of TREM2 using an activating antibody, AL-002a, modulates the 
immune response by increasing gene expression levels of both pro- and anti-
inflammatory cytokines and chemokines (discussed in detail in Chapter 2). Our 
data also demonstrate that systemic treatment with AL-002a significantly 
enhances the number of microglia clustered around congophillic amyloid plaques 
(discussed in detail in Chapter 2). Most importantly, our data demonstrate the 
efficacy of AL-002a in reducing amyloid deposition and subsequently improving 
cognition in the 5XFAD model of AD (discussed in detail in Chapter 2).  
Data supporting the role for microglia in Ab clearance is undoubtedly 
compelling. Yet, these data raise an interesting question: Why does Ab continue 
to accumulate and drive the progression of AD pathology despite paralleled 
microglia recruitment in humans? Several possible explanations have been 
suggested, of which two will be discussed here. One possible explanation for this 
well-described phenomenon is that microglia simply become overwhelmed by 
enhanced amyloidogenic processing and are unable to clear Ab at the same pace 
it is being generated. Another possible explanation is that, as AD pathology 
continues to progress, the phenotype of accumulating microglia changes resulting 
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in the loss of Ab-clearing capabilities. Though numerous studies support both of 
these explanations, one in particular makes them cohesive. In 2008, Hickman et 
al. demonstrated that as APP/PS1 mice age their microglia become dysfunctional 
[267]. In this study, microglia that exhibited a significant decrease in their 
expression of homeostatic Ab-binding receptors and Ab degrading enzymes were 
deemed dysfunctional [267]. Interestingly, these dysfunctional microglia were 
found to retain their ability to produce pro-inflammatory cytokines, which have been 
shown to down-regulate expression of Ab phagocytic receptors on microglia [267].  
This finding brings us back to the differential roles of acute and chronically 
sustained neuroinflammation; When microglia recognize a pathogen under 
homeostatic conditions the subsequent response quickly resolves pathology, 
providing an immediate benefit to the surrounding tissue. By contrast, in AD, the 
ongoing generation of pathogenic Ab species and the positive feedback loops 
between neuroinflammation and amyloidogenic processing prevent cessation of 
inflammation [271]. Chronically sustained inflammation, in turn, results in 
additional accumulation of Ab (likely due to the down-regulation of Ab  phagocytic 
receptors by pro-inflammatory cytokines) and neuronal debris (likely intensified by 
bystander damage of otherwise healthy neurons) which in turn may further activate 
factors that maintain a chronic, non-resolving inflammatory response [267]. Thus, 
it is hypothesized that the sustained exposure to Ab and pro-inflammatory 
cytokines and chemokines is responsible for the persistent functional impairment 
of microglial cells observed near sites of amyloid pathology [273, 274]. Additional 
support for this hypothesis arises from studies of the autophagy protein Beclin-1. 
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Beclin-1 is downregulated in in brains of AD patients and its reduction is said to 
interfere with efficient phagocytosis due to deficient CD36 and TREM2 receptor 
recycling [275].  
Importantly, microglia are not the only immune cells secreting pro-
inflammatory cytokines. Rather, several studies have shown that Ab deposition 
induces the recruitment of circulating monocytes to the brain parenchyma [228-
231]. Bone-marrow-derived (BMD) macrophages, which originate essentially from 
infiltrated pro-inflammatory monocytes, exhibit elevated levels of proteins 
necessary for antigen presentation and are, therefore, proposed to be more 
efficient at preventing or eliminating Ab [232-234]. The precise contribution of BMD 
macrophages in AD remains unclear to date, though several studies have 
implicated a spatial association between BMD macrophages and senile amyloid 
plaques [232].  
In addition to peripheral immune cells, components of the complement 
cascade can aid in exacerbating the immune response. The complement cascade 
is a well-characterized part of the innate immune system that promotes 
inflammation to enhance the ability of phagocytes to clear pathogens [276]. In the 
central nervous system (CNS), neurons, astrocytes, oligodendrocytes, and 
microglia express complement receptors [276]. Moreover, microglia and 
astrocytes can synthesize complement components and this synthesis can be 
modulated by various pro-inflammatory cytokines as well as the binding of Ab to 
toll-like receptors (TLRs) on the surface of microglia [277-281]. Thus, in AD, the 
accumulation of Ab induces complement activation which can be further 
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exacerbated by a disturbed balance between complement activators and 
regulators, which is also seen in AD [79, 282-284]. The latter becomes increasingly 
problematic throughout AD progression considering there is a naturally limited 
neuronal expression of complement regulators, which likely underlies the 
susceptibility of neurons to complement activation [276].  
Astrocytes are yet another mediator of neuroinflammation in AD. In post-
mortem human tissue as well as AD mouse models both activated microglia and 
hypertrophic reactive astrocytes accumulate around senile plaques [285, 286]. 
Similar to microglia, astrocytes become activated, or reactive, in response to a 
variety of CNS pathologies. Upon exposure to a pathogen such as Ab, astrocytes 
upregulate their expression of GFAP, their cellular processes hypertrophy, and 
they release cytokines, interleukins, nitric oxide, and other potentially neurotoxic 
molecules [287]. The work of Ben Barres and colleagues recently used 
transcriptome analysis to identify two distinct reactive states of astrocytes: A1 and 
A2. Akin to the polarization of activated macrophages to a pro-inflammatory M1 or 
anti-inflammatory M2 phenotype, A1 astrocytes upregulate a number of 
proinflammatory genes (e.g., complement cascade genes such as those encoding 
C1q) that have been previously shown to be destructive to synapses. Conversely, 
A2 astrocytes upregulate neurotrophic factors which promote the survival and 
growth of neurons [288]. Although the reactive profiles of astrocytes are only 
beginning to be characterized, it is widely accepted that different types of reactive 
astrocytes are induced by different types of injury.  
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In the context of AD, in addition to other human neurodegenerative 
diseases, A1 astrocytes are the most abundant [288]. Interestingly, the work of 
Ben Barres and colleagues has also recently demonstrated that activated, pro-
inflammatory microglia are responsible for the induction of this neurotoxic A1 
phenotype [289]. As previously discussed, microglia can secrete a variety of 
cytokines including IL-1a, TNFa, and C1q. Ben Barres and colleagues found that 
secretion of the aforementioned cytokines is both necessary and sufficient to 
induce the A1 reactive astrocyte profile and that A1 astrocytes fail to promote 
neuronal survival, outgrowth, synaptogenesis, and phagocytosis, instead gaining 
neurotoxic functions that ultimately induce the death of neurons and mature 
oligodendrocytes [289]. This potentially neurotoxic role of a subset of astrocytes is 
further supported by a study in which AAV-driven suppression of 
calcineurin/nuclear factor of activated T cells (NFAT) signaling reduced 
astrogliosis, decreased Ab deposition, and improved cognition in the APP/PS1 
model of AD [290].  
Taken together, these data suggest that the deposition of Ab activates 
microglia, inducing an acute neuroinflammatory response designed to clear Ab but 
that, over time, microglia become overwhelmed by the accelerated pathogenic 
production of Ab and simply cannot clear it at the same pace it is being generated. 
Data further suggest this inability of microglia to clear Ab arises due to chronically 
sustained inflammation, which does not result solely from microglia. Rather, 
binding of Ab to TLRs on microglia induces the complement cascade, in turn, 
producing C1q and further exacerbating the production and secretion of 
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proinflammatory mediators such as IL-1a and TNFa which, together with C1q, 
induce the A1 reactive astrocyte phenotype. Studies suggest the consistent 
production and secretion of proinflammatory mediators ultimately induces the 
down-regulation of Ab phagocytic receptors on microglia.  
Granted, chronically sustained neuroinflammation is also problematic from 
the standpoint of vascular integrity. Expression of matrix metalloproteinases 3 and 
9 (MMP3 and MMP9, respectively) can be influenced by the presence of 
proinflammatory cytokines. Matrix metalloproteinases (MMPs) are a family of 
enzymes collectively responsible for extracellular matrix degradation and turnover. 
MMP9 belongs to the gelatinase family of MMPs and can therefore degrade 
gelatin, cytokines, and even Ab  [254, 255]. Given its variety of substrates, MMP9’s 
expression is tightly regulated by a number of cytokines, growth factors, and other 
proteins. In particular, MMP9 expression is induced by the proinflammatory 
cytokines TNFa and IL-1b [256, 257]. Due to the necessity of its tight regulation, 
MMP9 is secreted as a zymogen (proMMP9) that requires cleavage by MMP3, the 
expression of which is also induced by pro-inflammatory cytokines, to become 
active [258]. Interestingly, recent evidence suggests that vascular amyloid 
contributes to enhanced MMP9 expression [254]. Isolated rat brain microvessels 
exposed to increasing concentrations of Ab1-40, the Ab species associated with 
cerebral amyloid angiopathy (CAA), exhibited increased MMP9 expression and 
decreased expression of the tight junction proteins claudin-1 and claudin-5 [291]. 
Similarly, microvessels isolated from Tg2576 AD transgenic mice displayed 
increased MMP9, decreased claudin-1 and claudin-5, and increased permeability 
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[292]. Several additional studies have further implicated MMP9 in tight junction 
degradation, blood-brain-barrier (BBB) breakdown, and subsequent disruption of 
the neurovascular unit. These implications are ultimately supported by the 
presence of MMP9 in hemorrhagic areas [254].   
The neurovascular unit is comprised of neurons, astrocytes, pericytes, 
endothelial cells, oligodendrocytes, and microglia (Figure 5.1). It functions to 
regulate local cerebral blood flow (CBF), BBB permeability, and neurovascular 
remodeling [293, 294]. The roles of endothelial cells and astrocytes in maintaining 
the integrity of the neurovascular unit are of particular importance here. Endothelial 
cells line the cerebral vasculature forming the BBB, tight junctions of which express 
specific transporters and thereby limit the passage of substrates between cells 
[295]. Astrocytes aid in supporting and protecting neurons by maintaining 
homeostatic concentrations of specific ions and neurotransmitters and also 
regulate CBF by directly interacting with endothelial cells through their specialized 
end-feet processes [295]. The cerebrovasculature of the brain is almost completely 
ensheathed by astrocytic processes called astrocytic end-feet. The astrocytic end-
foot is a specialized unit that functions to maintain ionic and osmotic homeostasis 
of the brain and does so through the expression of specific channels [296, 297]. 
End-feet enriched channels include aquaporin 4 (AQP4), the inwardly rectifying K+ 
channel Kir4.1, and the Ca2+-dependent K+ channel MaxiK, or BK [298, 299]. The 
astrocytic end-foot is anchored to the vascular basement membrane via the a-b 
dystroglycan complex [300, 301]. 
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An essential function of the astrocytes surrounding neurons of the 
neurovascular unit is to maintain the neuronal resting membrane potential (RMP) 
by controlling the extracellular potassium concentration, a process referred to as 
potassium siphoning or buffering [302]. Following an action potential, astrocytes 
take up excess K+ ions via their Kir4.1 channels and move these ions through their 
connexin 43-containing gap junctions into the circulation using the astrocytic end-
feet [303, 304]. Recall that ionic movement across cell membranes is commonly 
coupled to the movement of water and the maintenance of osmotic equilibrium and 
that most water movement into and out of the cells occurs via water channels 
known as aquaporins [305]. The AQP4 channel is expressed by astrocytes in the 
neurovascular unit and is highly polarized to the end-foot membrane [306]. 
Notably, dislocalization of AQP4 from the astrocytic end-feet is associated with 
potassium clearance deficits in transgenic mice [306]. Studies also suggest that 
astroglial-mediated interstitial fluid bulk flow through AQP4 facilitates the transport 
of Ab across the BBB into the blood, ultimately clearing it from the brain [307, 308]. 
Thus, AQP4 appears to play two equally important roles. Importantly, the Kir4.1, 
AQP4, and BK channels share a common anchoring protein known as Dp71 which 
complexes with a-syntrophin to form the end-foot anchoring complex [306]. MMP9 
has been shown to be a major degrading enzyme of the dystroglycans [309], 
suggesting that activation of MMP9 degrades the dystrophin-dystroglycan complex 
anchoring the end-foot to the basement membrane of the vasculature. This 
degradation in turn is can lead to dislocalization of AQP4, Kir4.1 and BK from the 
vasculature, thereby impairing potassium homeostasis and neurovascular 
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coupling [306, 310]. Thus, chronic secretion of pro-inflammatory cytokines, in 
particular TNFa and IL-1b, not only induces the down-regulation of Ab phagocytic 
receptors on microglia, but enhances the expression of MMP9 which can 
negatively impact the vasculature and simultaneously induce bystander damage 
to otherwise healthy neurons. 
The work presented in chapters 3 and 4 demonstrates that neither acute 
nor systemic co-administration of the anti-Ab and AL-002a antibodies additively 
reduces Ab deposition. However, it also shows that AL-002a has similar efficacy 
as an N-terminal targeted anti-Ab antibody in the reducing Ab deposition when 
administered intracranially and preventing the additional deposition of Ab when 
administered systemically. Notably, treatment with the anti-Ab antibody was shown 
to significantly increase the incidence of microhemorrhage whereas reduction of 
Ab by AL-002a was shown to occur in the absence of cerebrovascular pathology. 
The absence of cerebrovascular pathology following treatment with AL-002a, but 
not the anti-Ab antibody, is likely due to the observed differences in immune 
modulation and MMP9 expression.  
Biochemical quantification of a number of cytokines revealed that treatment 
with AL-002a significantly increases levels of the anti-inflammatory cytokine IL-10, 
whereas treatment with the anti-Ab antibody significantly increases levels of TNFa, 
IL-1b, IL-12, IL-6, IL-2, and KC/GRO (CXCL1), all of which are considered to be 
pro-inflammatory. In addition to discrepancies in immune modulation, our data 
demonstrate that treatment with the anti-Ab antibody, but not AL-002a, induces 
increased expression of MMP3 and MMP9. Our data thereby suggest AL-002a and 
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the anti-Ab antibody function differently to reduce Ab deposition in the brains of 
5XFAD mice (Figure 2). It is likely that increased levels of the proinflammatory 
cytokines TNFa and IL-1b following treatment with the anti-Ab antibody are directly 
responsible for the observed upregulation of MMP3 and MMP9 and subsequent 
increased incidence of microhemorrhage. Our data, therefore, have important 
implications for AD clinical trials. 
Despite significant mouse model data demonstrating both pathological and 
cognitive efficacy of anti-Ab immunotherapy, clinical trials continue to fail to meet 
primary endpoints for efficacy. Moreover, a number of trials reported occurrences 
of cerebrovascular adverse events characterized by treatment-related 
abnormalities on brain imaging. Amyloid related imaging abnormalities (ARIA) 
were first identified in the Bapineuzumab trial and have since been verified by a 
number of subsequent anti-Ab immunotherapy trials [112-114]. ARIA come in two 
flavors: 1) ARIA-E, thought to represent vasogenic edema, and 2) ARIA-H, thought 
to represent microhemorrhages.  
ARIA-E is observed as an increased, hyperintense MR signal on FLAIR 
sequences [116] and is typically a transient phenomenon. ARIA-E is said to be 
transient due to its reversible nature; It resolves either spontaneously following the 
cessation of anti-Ab immunotherapy treatment or with steroid treatment [116]. On 
a cellular level, ARIA-E is hypothesized to represent increased extracellular fluid 
volume that arises due to the increased permeability of capillary endothelial cells 
to serum proteins [116]. Granted, given there is no histopathological correlate for 
ARIA-E, it is difficult to be certain that ARIA-E is in fact related to underlying 
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vasogenic edema. Notably, CAA is another condition presenting neuroimaging 
features similar to ARIA associated with anti-Ab immunotherapy [116, 311, 312]. 
CAA related inflammation is hypothesized to arise from an inflammatory response 
to the vascular amyloid deposits. Following its resolution either spontaneously or 
with steroid treatment, CAA imaging findings also reverse [116]. ARIA-E and CAA 
also have a shared association with ApoE4 carrier status [313]; ApoE4 carriers 
have been shown to exhibit increased vascular amyloid deposition, and the Phase 
2 Bapineuzumab trial revealed ApoE4+ participants had a significantly increased 
incidence of ARIA-E [113]. Thus, there is a likely association of the inflammatory 
response to vascular amyloid and the incidence of ARIA-E. Interestingly, treatment 
with both the anti-Ab and AL-002a antibodies, as well as a combination of the two, 
was shown to increase soluble Ab1-40 levels, the Ab species comprising vascular 
amyloid in CAA (discussed in detail in chapter 4). It is possible that treatment with 
these antibodies results in the disaggregation of Ab oligomers and the restoration 
of their solubility [120], which may augment Ab efflux from the brain through 
perivascular drainage pathways or via low-density lipoprotein receptor related 
protein-1 (LRP1) [242, 243]. However, this could potentially contribute to ARIA-E 
considering the mobilization of Ab to perivascular drainage pathways that are 
impaired could induce transient paradoxical increases in vascular amyloid 
deposition following anti-Ab immunotherapy [114]. In fact, this concept has been 
demonstrated in a number of human neuropathological studies [42-44]. It will, 
therefore, be important to assess the presence of ARIA-E in future studies with AL-
002a. Granted, given that treatment with AL-002a did not induce 
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microhemorrhages, we remain hopeful that FLAIR imaging will show the absence 
of ARIA-E following AL-002a treatment.  
ARIA-H manifests as a low-intensity signal on T2* MRI or susceptibility-
weighted imaging (SWI) and is thought to represent iron deposits indicative of a 
small leakage of blood from a vessel into the adjacent brain parenchyma 
(microhemorrhage) or subarachnoid space (superficial siderosis) [112]. In AD, 
microhemorrhages are attributed to leakage of blood from damaged vessels, 
particularly those with enhanced amyloid deposition (i.e. CAA) [314]. The 
aforementioned inflammatory response to vascular amyloid is hypothesized to 
weaken the vessel wall, increasing the risk of hemorrhagic events into the adjacent 
parenchyma and forming a microhemorrhage [116]. It should be noted that the 
prevalence of microhemorrhage is significantly increased in individuals with 
cardiovascular risk factors [315] and that the greater number of microhemorrhages 
at baseline confers greater risk of subsequent microhemorrhages [316].  
To date, there is limited information regarding the relationship between 
ARIA-E and ARIA-H, however, their relation to dose in the bapineuzumab trials 
suggests ARIA may arise due to enhanced clearance of parenchymal amyloid from 
the brain parenchyma into the vasculature [112, 113]. Hypotheses suggest the 
rapid movement of amyloid from the parenchyma into the perivascular space 
creates a drainage backup resulting in excess fluid shifts and vasogenic edema 
and that extraction of amyloid from the vasculature results in enhanced 
permeability and fragility of brain capillaries [116]. Assuming vessel wall integrity 
is sufficiently compromised, this proposed mechanism could explain the increased 
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incidence of microhemorrhages following the administration of amyloid-modifying 
therapies.   
Notably, cerebrovascular adverse events have not only been problematic 
for passive immunization strategies, but active immunization strategies as well. In 
1999, Schenk and colleagues demonstrated that active peripheral immunization 
with the full-length Ab1-42 peptide led to the prevention of plaque formation and the 
removal of existing plaques in a transgenic mouse model [98]. In 2000, Morgan et 
al. verified that the removal of existing plaques resulted in enhanced cognition 
[100]. Together, these studies inspired the first clinical trial of Ab immunization in 
Alzheimer’s disease. This trial involved 80 patients with mild to moderate AD, 64 
of which received active immunization with synthetic Ab1-42 (AN1792). Though the 
AN1792 trial was ultimately stopped due to 6% of participants developing acute 
meningoencephalitis [104], post-mortem studies from AN1792 participants 
confirmed that plaque removal occurred in those that received AN1792 [42, 43]. 
However, this plaque removal was found to have little to no effect on cognitive 
outcome measures [42, 43]. Interestingly, a consistent feature of the published 
post-mortem AN1792 cases was the persistence of vascular amyloid despite the 
reduction in parenchymal amyloid [44].  
As stated, our data show the AL-002a and anti-Ab antibody modulate the 
immune response differently in order to reduce Ab deposition in the brains of 
5XFAD mice. It is likely that increased levels of the proinflammatory cytokines 
TNFa and IL-1b following treatment with the anti-Ab antibody are directly 
responsible for the observed upregulation of MMP3 and MMP9 and subsequent 
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increased incidence of microhemorrhage. An in vitro study using BV2 cells treated 
with either an anti-Ab IgG-Ab or anti-tau IgG-tau immune complex demonstrated 
increased MMP3 and MMP9, suggesting that activation of MMP9 requires the Fcg 
receptor, the surface receptor activated by the anti-Ab antibody [259]. Increased 
levels of CXCL1 following treatment with the anti-Ab antibody, but not AL-002a, 
suggests enhanced infiltration of peripheral immune cells which may further 
exacerbate levels of pro-inflammatory cytokines with little benefit to the AD brain. 
Conversely, the absence of cerebrovascular pathology in the 5XFAD mice treated 
with AL-002a is likely due to increased levels of IL-10. As discussed previously, IL-
10 inhibits the production of proinflammatory cytokines, thereby preventing the 
production of MMP3 and MMP9 and, in turn, tight junction breakdown and BBB 
leakage. Thus, activation of the microglial Fcg receptor results in activation of 
MMP9, the expression of which is further activated by the chronic upregulation of 
TNFa and IL-1b, whereas activation of the microglial TREM2 receptor does not. 
The lack of cerebrovascular pathology following treatment with AL-002a 
demonstrates that agonizing TREM2 may be effective for the treatment of LOAD, 
and highlights the fact that, although treatment with AL-002a has implications for 
Ab deposition, AL-002a does not directly target Ab. Rather, AL-002a modulates 
the immune response in a way that appears to be beneficial and may have 
implications for other AD-associated pathologies. That being said, there are 
several limitations to our studies that are worth noting.  
Firstly, some of the data presented here appears contradictory. 
Immunohistochemistry data presented in chapter 2 demonstrates reductions in Ab 
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following treatment with AL-002a, however, follow-up studies presented in 
chapters 3 and 4 do not reproduce these findings. Instead data presented in 
chapter 3 demonstrates that acute treatment with AL-002a results in trending, but 
non-significant, reductions in Ab whereas data presented in chapter 4 shows no 
reductions in Ab following chronic treatment with AL-002a. These discrepancies in 
Ab clearance may be attributable to the fact that two different anti-Ab antibodies 
were used in these studies; immunohistochemistry data in chapter 2 was 
generated using an anti-Ab antibody that binds the N terminus (amino acids 1-16) 
of the Ab peptide, whereas data in chapters 3 and 4 were generated using the 4G8 
antibody, which binds the middle portion of the Ab peptide (amino acids 17-24). 
Given that the anti-Ab antibody being injected binds the N terminus of the Ab 
peptide it was necessary to use 4G8 in order to avoid potential antigen masking, 
however, this may have also contributed to the discrepancies in Ab clearance 
observed between datasets.  
The fact that acute administration of AL-002a showed trending, but non-
significant, reductions in Ab (chapter 3) while chronic administration of AL-002a 
failed to show any reductions in Ab (chapter 4) is not trivial. These differences are 
likely due to the fact that in the acute administration study, AL-002a was directly 
injected into the brain whereas AL-002a was required to cross the BBB in the 
systemic study. Given that, on average, only 0.1% of systemically injected 
antibodies successfully cross the BBB this could represent a significant clinical 
challenge moving forward. It would be interesting to repeat these studies using 
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focused ultrasound, a non-invasive technology that enables reversible opening of 
the BBB to enhance the delivery of therapeutics.  
Additionally, qPCR data presented in chapter 2 demonstrates that both 
intracranial (acute) and intraperitoneal (systemic) administration of AL-002a 
upregulates pro- and anti-inflammatory cytokines, and among those increased are 
TNFa and IL1b. This in and of itself is interesting given that anti-Ab antibodies 
have only been shown to increase pro-inflammatory gene expression and, in some 
cases, decrease the anti-inflammatory gene expression. However, increases in 
levels of TNFa and IL1b were not recapitulated following systemic administration 
of AL-002a in a follow-up study (chapter 4). Rather, data presented in chapter 4 
showed decreased levels of the aforementioned cytokines following treatment with 
AL-002a. This discrepancy is likely due to the fact that data presented in chapter 
2 is indicative of gene expression levels whereas that from chapter 4 is indicative 
of protein expression levels and levels of mRNA transcripts alone are not sufficient 
to predict protein levels (Reviewed in [317]).  
Furthermore, it is important to recognize that Alzheimer’s disease effects 
the brain in a sexually dimorphic manner, adding a layer of complexity to the design 
of AD therapeutics. 5XFAD mice have been shown to exhibit sex-dependent 
differences in amyloid deposition [61, 217]. Thus, in order to avoid biasing our data, 
our study only used male mice. Considering in humans the incidence of 
Alzheimer’s disease is higher in women than in men, these studies need to be 
repeated in female transgenic mice. As discussed, vascular amyloid load has been 
shown to affect the incidence of cerebrovascular adverse events. Unfortunately, 
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the CAA load in the 5XFAD model of AD is highly variable, making data 
interpretation somewhat unreliable. Repeating these studies in transgenic mice 
with vascular amyloid deposition is crucial for understanding the viability of TREM2 
agonization as a therapeutic strategy for individuals with cardiovascular risk 
factors. By the same token, repeating these studies in amyloid-depositing 
transgenic mice crossed with mice expressing different humanized ApoE isoforms 
will also be critical in understanding the viability of AL-002a as a “one-size-fits-all” 
immunotherapy. Determining the effects of AL-002a treatment on the integrity of 
astrocytic end-feet will also be important for confirming that AL-002a does not 
negatively impact the vasculature. Finally, several studies have shown that TREM2 
ameliorates neuronal tau pathology via the suppression of the microglial pro-
inflammatory response, thereby implicating a neuroprotective role for TREM2 
against tau pathology [318, 319]. Though data from previous anti-Ab 
immunotherapy studies in humans suggest tau is largely unaffected by anti-
Ab antibodies, agonization of TREM2 using AL-002a may yield different results 
due to the altered microglial immune phenotype presented here. It will, therefore, 
be important to repeat these studies in a transgenic tau model to determine the 
effects of AL-002a treatment on tau pathology.  
In conclusion, irrespective of these inherent limitations, our data advocate 
that agonism of TREM2 is a viable therapeutic strategy for the treatment of LOAD 
that lacks the limitation of cerebrovascular adverse events normally observed with 
existing anti-Ab immunotherapies (Figure 5.2).  
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Figure 5.1: Schematic showing the arrangement of cells of the neurovascular 
unit. 
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Figure 5.2: The proposed mechanisms by which the anti-Ab antibody, but 
not AL-002a, induces cerebrovascular adverse events.   
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